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Abstract
Signaling by receptor tyrosine kinases (RTKs) typically involves binding of extracellular ligands and
subsequent activation of intracellular kinase domain, which in turn mediates autophosphorylation and
downstream signal transduction. However, several RTKs, such as ErbB3 (HER3) and Ryk/Derailed, lack key
conserved (and catalytically important) residues in their intracellular kinase domain, and are thought to be
inactive `pseudo'-kinases. Much less is known regarding how these receptor tyrosine `pseudo'-kinases mediate
transmembrane signaling. The work described in this dissertation attempts to understand the non-canonical
signaling by ErbB3 and Ryk/Derailed using a combination of biophysical, biochemical and cell biology
methods. ErbB3 is one of four members of the human epidermal growth factor receptor (EGFR) family.
ErbB3 signals primarily by heterodimerizing with ErbB2 (HER2) and mediates resistance of tumor cells to
EGFR/ErbB2-targeted therapeutics. We have investigated the role of ErbB3 `pseudo'-kinase domain in its
signaling. In vitro enzymology study shows that, despite the sequence alterations, ErbB3 kinase domain binds
ATP with high affinity and possesses weak kinase activity to trans-autophosphorylate its intracellular region.
We also describe a crystal structure of ErbB3 kinase, which resembles the inactive EGFR and ErbB4 kinase
domains. Whereas mutations that destabilize this configuration activate EGFR and ErbB4 (and promote
EGFR-dependent lung cancers), a similar mutation conversely compromises ErbB3's ability to activate
downstream Akt signaling in our cellular studies. These findings suggest that ErbB3 kinase may be crucial for
signaling and could represent an important therapeutic target. Ryk and its Drosophila homolog Derailed
(Drl) contain an extracellular Wnt Inhibitory Factor (WIF) domain and participate in non-canonical Wnt
signaling. We attempt to understand, for the first time, the molecular mechanism of Ryk/Drl-Wnt interaction
using Drl as a model system. We show that Drl binds directly to Drosophila Wnt5 (DWnt5) with
submicromolar affinity using surface plasmon resonance (SPR). X-ray crystallography study has identified a
conserved binding site of Drl for DWnt5. Mutating this site abolishes DWnt5 binding by Drl. This study
serves as a starting point for our understanding of Wnt signaling by Ryk/Drl at a molecular level.
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ABSTRACT 
SIGNALING BY NON-CANONICAL RECEPTOR TYROSINE KINASES  
ERBB3 AND RYK  
Fumin Shi 
Mark A. Lemmon 
Signaling by receptor tyrosine kinases (RTKs) typically involves binding of 
extracellular ligands and subsequent activation of intracellular kinase domain, which in 
turn mediates autophosphorylation and downstream signal transduction. However, 
several RTKs, such as ErbB3 (HER3) and Ryk/Derailed, lack key conserved (and 
catalytically important) residues in their intracellular kinase domain, and are thought to 
be inactive ‗pseudo‘-kinases. Much less is known regarding how these receptor tyrosine 
‗pseudo‘-kinases mediate transmembrane signaling. The work described in this 
dissertation attempts to understand the non-canonical signaling by ErbB3 and 
Ryk/Derailed using a combination of biophysical, biochemical and cell biology methods.  
ErbB3 is one of four members of the human epidermal growth factor receptor 
(EGFR) family. ErbB3 signals primarily by heterodimerizing with ErbB2 (HER2) and 
mediates resistance of tumor cells to EGFR/ErbB2-targeted therapeutics. We have 
investigated the role of ErbB3 ‗pseudo‘-kinase domain in its signaling. In vitro 
enzymology study shows that, despite the sequence alterations, ErbB3 kinase domain 
binds ATP with high affinity and possesses weak kinase activity to trans-
autophosphorylate its intracellular region. We also describe a crystal structure of ErbB3 
kinase, which resembles the inactive EGFR and ErbB4 kinase domains. Whereas 
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mutations that destabilize this configuration activate EGFR and ErbB4 (and promote 
EGFR-dependent lung cancers), a similar mutation conversely compromises ErbB3‘s 
ability to activate downstream Akt signaling in our cellular studies. These findings 
suggest that ErbB3 kinase may be crucial for signaling and could represent an important 
therapeutic target. 
Ryk and its Drosophila homolog Derailed (Drl) contain an extracellular Wnt 
Inhibitory Factor (WIF) domain and participate in non-canonical Wnt signaling. We 
attempt to understand, for the first time, the molecular mechanism of Ryk/Drl-Wnt 
interaction using Drl as a model system. We show that Drl binds directly to Drosophila 
Wnt5 (DWnt5) with submicromolar affinity using surface plasmon resonance (SPR). X-
ray crystallography study has identified a conserved binding site of Drl for DWnt5. 
Mutating this site abolishes DWnt5 binding by Drl. This study serves as a starting point 
for our understanding of Wnt signaling by Ryk/Drl at a molecular level.  
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Chapter 1 
Characterization of ErbB3 Tyrosine Kinase Domain 
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1.1  Introduction to Receptor Tyrosine Kinase ErbB3  
1.1.1 Overview of ErbB Family Receptor Tyrosine Kinases 
Human ErbB receptor tyrosine kinases (RTKs), including ErbB1 (EGFR), ErbB2 (HER2), 
ErbB3 (HER3) and ErbB4 (HER4), are type I transmembrane proteins that mediate 
cellular responses to an array of extracellular ligands (Yarden and Sliwkowski 2001; 
Hynes and MacDonald 2009). Each receptor contains an extracellular ligand binding 
region, a single transmembrane helix, and an intracellular tyrosine kinase domain (TKD) 
that is flanked by juxtamembrane and C-terminal regulatory regions (Baselga and Swain 
2009; Hynes and MacDonald 2009) (Figure 1.1, left). Upon ligand binding to the 
extracellular region, ErbB receptors undergo homo- or hetero- dimerization (Lemmon 
2009), bringing their intracellular TKDs close to each other. The proximity of the 
intracellular domains (ICD) induces allosteric trans-activation of enzymatic activity, 
mediating the phosphoryl transfer of ATP γ-PO4 to the side chain of multiple tyrosines on 
the receptor‘s C-tail (Zhang, Gureasko et al. 2006; Jura, Endres et al. 2009; Red Brewer, 
Choi et al. 2009). Phosphorylation of tyrosines creates docking sites for recruitment of 
various signaling molecules, which activates downstream signaling cascades (such as 
MAPK and Akt pathways) and ultimately triggers cell proliferation and survival (Yarden 
and Sliwkowski 2001) (Figure 1.1, right). In a pathological setting, aberrant ErbB 
signaling via either ErbB protein overexpression or mutation plays an important 
oncogenic driver role in the development of various cancers.  
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Figure 1.1: Scheme of ligand induced ErbB activation (shown in the figure is signaling of the ErbB2/ErbB3 
heterodimer). ECD: extracellular domain; TM: transmembrane domain; JM: juxtamembrane domain; TKD: 
tyrosine kinase domain. Grey circles (Y): tyrosine residues; Red circles (pY): phosphor-tyrosines; Orange 
circles (L): ligand. 
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1.1.2 Introduction to ErbB3 Signaling 
ErbB3 (HER3) stands out among the four mammalian ErbB receptors due to two special 
properties. Firstly, it is the only ErbB protein that contains an atypical kinase domain. 
When first cloned (Kraus, Issing et al. 1989; Plowman, Whitney et al. 1990), it was noted 
that ErbB3 contains amino acid substitutions at two particular sites that are highly 
conserved in other known kinases (Hanks, Quinn et al. 1988). Since these two residues 
are involved in maintaining the active conformation and mediating the phosphoryl 
transfer reaction, the ErbB3 kinase was suggested to be catalytically defective, and some 
evidence was reported to this effect (to be discussed further in the following sections)  
(Citri, Skaria et al. 2003).  
Secondly, binding of neuregulin ligands to ErbB3 fails to induce ErbB3 homo-
dimerization, and can only induce the formation of heterodimers between ErbB3 and 
other ErbBs (Ferguson, Darling et al. 2000; Citri, Skaria et al. 2003; Berger, Mendrola et 
al. 2004).  Mixing neuregulin1β (Nrg1β) with recombinant ErbB3 extracellular domain 
protein failed to induce homodimerization of the latter (monitored by analytical ultra-
centrifugation) (Ferguson, Darling et al. 2000). Using an ErbB3 ECD/EGFR ICD 
chimeric protein, Berger et al. also showed that neuregulin cannot stimulate 
autophosphorylation of this chimeric protein (or downstream signaling when it is 
expressed in Drosophila S2 cells), unless ErbB2 protein is also expressed in the same cell 
(allowing heterodimerization). In contrast, neuregulin induces a robust signaling response 
in S2 cells expressing ErbB4 alone (Berger, Mendrola et al. 2004).  
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Among all ErbB heterodimers that ErbB3 can form, the ErbB2/ErbB3 
heterodimer is generally considered to be the most potent mitogenic signaling complex in 
the ErbB receptor network (Citri, Skaria et al. 2003; Holbro, Beerli et al. 2003). In cells 
that contain only these two ErbB receptors, both ErbB2 and ErbB3 are extensively 
tyrosine phosphorylated upon neuregulin stimulation (Riese, van Raaij et al. 1995). Due 
to the presence of multiple C-tail phosphotyrosine binding sites for the p85 subunit of 
PI3K, ErbB3 is highly effective in activating the PI3K-Akt pathway that leads to cell 
survival and proliferation (Prigent and Gullick 1994; Soltoff, Carraway et al. 1994; 
Hellyer, Cheng et al. 1998), whereas ErbB2 is mainly responsible for activating the 
MAPK pathway through Grb2/Sos recruitment (Figure 1.1). When ErbB signaling is 
activated abberantly, cancer results. The ErbB2/ErbB3 heterodimer has been proposed as 
an ―oncogenic unit‖ due to its potency in eliciting mitogenic and transforming signals 
(Holbro, Beerli et al. 2003). Tumor mice models using transplantation of ErbB 
transfected NIH-3T3 cells have shown that overexpression of ErbB2/ErbB3 causes the 
most aggressive tumor growth compared with other ErbB combinations (Alaoui-Jamali, 
Song et al. 2003).  
1.1.3 ErbB3 in Cancer Development and Corresponding Therapeutics 
Numerous studies have demonstrated an important role for aberrant ErbB3 signaling in 
various cancers, including breast (Holbro, Beerli et al. 2003; Lee-Hoeflich, Crocker et al. 
2008), prostate (Soler, Mancini et al. 2009), lung (Engelman, Janne et al. 2005), ovarian, 
colon and gastric cancers (Sithanandam and Anderson 2008). 
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The role of ErbB3 is best characterized in breast cancer. Data from in vitro and 
mouse models, plus clinical studies in humans, all argue that the ErbB2/ErbB3 
heterodimer drives breast cancer progression (reviewed in (Hamburger 2008; Lee-
Hoeflich, Crocker et al. 2008)). Overexpression of ErbB2 and/or ErbB3 in breast cancer 
has been reported to correlate with poor prognosis (Travis, Pinder et al. 1996; Ferretti, 
Felici et al. 2007), whereas knockdown of ErbB2 or ErbB3 can markedly suppress the 
growth of breast cancer cells (Faltus, Yuan et al. 2004; Lee-Hoeflich, Crocker et al. 2008). 
As a result of these observations, inhibition of ErbB2/ErbB3 signaling has become a very 
attractive goal in the clinical treatment of breast cancer. Current efforts to suppress this 
signaling pathway have been mostly focused on ErbB2, targeting either the extracellular 
ligand-binding and dimerization region using therapeutic antibodies or intracellular 
kinase activity with small molecule inhibitors. Some of these ErbB2-targeted drugs, such 
as Herceptin and Tykerb (lapatinib), are among the most famous breast cancer drugs 
(Park, Neve et al. 2008) and have proven to be effective in some patients with breast 
cancer characterized by ErbB2 overexpression (Nahta and Esteva 2006; Bedard, Cardoso 
et al. 2009).  
Despite significant advances with ErbB2-directed therapies in breast cancer, 
effectiveness of these treatments is modest at best. These drugs work for only a small 
subset (<25%) of patients – even within the group showing ErbB2 gene amplification and 
overexpression (Chen, Xia et al. 2008), and development of resistance is a very 
significant problem (Chen, Xia et al. 2008; Bedard, Cardoso et al. 2009). ErbB3 has 
recently become a focus of attention, as it appears to play an important role in escape 
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from (or resistance to) therapeutic agents that target ErbB2 in cancer. Sergina et al. 
showed that the BT474 and SKBR3 breast cancer cell lines become resistant to gefitinib, 
an ErbB TKD inhibitor, within 24 hours of treatment, and this correlates with a recovery 
in ErbB3 (but not ErbB2) phosphorylation and corresponding Akt activation (Sergina, 
Rausch et al. 2007). Suppression of ErbB kinase activity with gefitinib also appeared to 
induce relocalization of the ErbB3 protein from intracellular compartments to the plasma 
membrane, which was proposed to facilitate its interaction with other ErbBs, contributing 
to inhibitor resistance. Similarly, breast cancer cell lines that are resistant to Herceptin 
(an ErbB2 antibody) can be inhibited by antibodies against ErbB3 (van der Horst, Murgia 
et al. 2005).   
ErbB3 also plays a similar role in drug resistance of non-small cell lung cancer 
(NSCLC) associated with EGFR overexpression or mutation. In gefitinib-sensitive 
NSCLC cell lines, ErbB3 is found to be associated with the PI3K p85 subunit and 
mediates signaling from activated EGFR to the downstream Akt pathway via PI3K.  
Alternatively, ErbB3 can contribute to the development of gefitinib resistance in NSCLC 
cell lines through partnering with another receptor tyrosine kinase MET. MET 
amplification causes hyper-phosphorylation of ErbB3 even in the presence of gefitinib. 
Similar ErbB3-mediated EGFR activation of Akt signaling has been reported in erlotinib 
sensitive pancreatic and colorectal tumor cell lines (Buck, Eyzaguirre et al. 2006).  
Consistent with these observations, down-regulation of ErbB3 using RNA interference 
(RNAi) can restore the sensitivity of cancer cells to gefitinib or erlotinib – with 
associated reduction of activated phospho-Akt levels. Where MET is involved, small 
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molecule inhibitors of its tyrosine kinase can also restore geftinib sensitivity (Engelman, 
Zejnullahu et al. 2007).  By contrast with these observations, gefitinib-resistant NSCLC 
cell lines show no detectable association of ErbB3 with PI3K-p85 or Akt sensitivity to 
ErbB3 knockdown (Engelman, Janne et al. 2005). 
Due to an increasing realization that ErbB3 is a key contributor to development of 
cancers and their drug resistance, many pharmaceutical companies are actively pursuing 
antibodies that specifically target ErbB3 in order to suppress its oncogenic signaling. One 
ErbB3 antibody called MM-121 (Merrimack Pharmaceuticals Inc.) has been developed to 
suppress ligand-induced ErbB3 phosphorylation in cancer cell lines and, when combined 
with the EGFR-targeted cetuximab antibody, it suppresses cetuximab resistance in a 
mouse lung cancer model driven by an EGFR T766M/L834R dual mutation (Schoeberl, 
Faber et al.). Multiple phase I&II clinical trials are currently being conducted to test the 
efficacy of this therapeutic agent in multiple settings. Other ErbB3-specific antibodies 
undergoing clinical trials include U3-1287 generated by U3 Pharma & Amgen and MP-
RM-1 by MediaPharma (Sala, Traini et al.). Recently, a novel dual-specific ErbB3/EGFR 
antibody, MEHD7945A, has been developed by Genentech, and has shown promising 
result in studies of suppression of solid tumors (Schaefer, Haber et al.).  MEHD7945A is 
currently in phase II clinical trials for squamous cell carcinoma of the head and neck and 
in a phase I clinical trial for epithelial tumors. Despite these developments, however, 
therapeutically inactivating ErbB3 through extracellular targeting with antibodies will be 
a challenging task, since the majority of ErbB3 has been reported to be located in 
intracellular compartments rather than at the cell surface (Sergina, Rausch et al. 2007).  
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 Whereas much effort has been put into inactivating ErbB3 with antibodies that 
target its extracellular regions, the ErbB3 kinase domain has been ignored so far. The 
primary reason for this is that ErbB3 has been deemed ―kinase-dead‖ due to the sequence 
alterations in its TKD mentioned above (Hanks, Quinn et al. 1988; Prigent and Gullick 
1994). Based on this notion, it has been assumed that all tyrosine phosphorylation in the 
ErbB2/ErbB3 heterodimer arises from ErbB2‘s kinase activity (Citri, Skaria et al. 2003; 
Holbro and Hynes 2004). This creates a problem, however, because studies of ErbB 
signaling mechanisms argue that autophosphorylation of ErbB receptors within ligand-
induced dimers occurs in trans, with each ErbB kinase mediating tyrosine 
phosphorylation of its dimerization partner (Honegger, Kris et al. 1989; Honegger, 
Schmidt et al. 1990; Lammers, Vanobberghen et al. 1990). According to this model, it is 
unclear how ErbB2 could become phosphorylated in an ErbB2/ErbB3 heterodimer unless 
ErbB3 carries an active kinase. Consistent with this possibility, recent studies of some 
other presumed ―pseudokinases‖, such as Wnk, CASK, VASP and KSR, have revealed 
that they do retain kinase activity in spite of previous sequence-based assumptions that 
they are ―kinase dead‖ (Min, Lee et al. 2004; Mukherjee, Sharma et al. 2008; Villa, 
Capasso et al. 2009; Brennan, Dar et al.). Similar to ErbB3, these presumed 
pseudokinases all contain sequence alterations at key conserved residues in their kinase 
domain, but can nonetheless catalyze the phosphoryl transfer reaction through non-
canonical mechanisms. It is therefore important to take a closer look at ErbB3‘s TKD, 
and to test the hypothesis that ErbB3, like other active pseudokinases, does in fact 
function as an active kinase to promote ErbB signaling. If this is the case, targeting the 
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ErbB3 kinase domain may be a promising and important novel therapeutic strategy in 
cancer treatment. 
1.1.4 Structure and Biochemistry of Tyrosine Kinase Domains 
To understand the special properties of ErbB3 kinase domain, we first need to discuss the 
general features of tyrosine kinase domains. The overall structure of protein kinase 
domains (both tyrosine kinases and Ser/Thr kinases) is highly conserved, comprising an 
N-lobe and a C-lobe (Figure 1.2A). The N-lobe contains five antiparallel β-strands and 
one α-helix (called αC), whereas the C-lobe is mostly α-helical. Binding sites for Mg-
ATP and phosphorylation substrate are located between these two lobes, next to the 
activation loop that links these two lobes. 
Several key regions and conserved residues around the active site have been 
implicated in kinase regulation and in catalysis itself (Figure 1.2B). For many protein 
kinases, trans-phosphorylation of key Ser/Thr/Tyr residue(s) in the activation loop 
prevents it from forming auto-inhibitory interactions and effectively stabilizes the active 
conformation of the kinase domain (Hubbard, Mohammadi et al. 1998).  However, it 
should be noted that this is not the case for EGFR (discussed in the following paragraphs). 
Coupled with release of the activation loop from its auto-inhibitory position is a re-
positioning of the αC helix in the N-lobe, which utilizes a Glu side-chain (replaced by 
His740 in ErbB3) to form an ion pair with the ε-amino group of a highly conserved Lys 
from the VAIK motif in β3 strand. The latter also interacts directly with the ATP α- & β- 
phosphates and promotes ATP binding in the active conformation (Huse and Kuriyan 
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2002). A Lys to Met mutation at this position impairs the kinase activity of most kinases 
(Qian, Levea et al. 1994). A conserved Asp residue (replaced by Asn815 in ErbB3) from 
an also-conserved HRD motif is located between the ATP γ-PO4 and the side chain of the 
substrate tyrosine, marked Asp1 in Figure 1.2B (Williams, Wang et al. 2000). Another 
key Asp from the conserved DFG motif (Asp2 in Figure 1.2B) is responsible for 
coordinating Mg
2+
 ions with ATP phosphate groups. Upon binding to the catalytic cleft 
of the TKD, the substrate peptide remains largely exposed to solvent. Consequently, 
unlike most enzymes, tyrosine kinases usually have low substrate specificity in vitro (Fan, 
Wong et al. 2005). 
The catalytic process of tyrosine kinases is still not fully understood. Since the 
major sequence alteration in the ErbB3 TKD is the substitution of the Asp in HRD motif 
(Asp1 in Figure 1.2B) with Asn815, the catalytic role of this key Asp is discussed here. 
This Asp was initially thought to function as a general base, deprotonating the tyrosyl 
side chain of the substrate so that the latter becomes a good nucleophile to attack the γ-
phosphate group of ATP in an associative manner (Stamos, Sliwkowski et al. 2002). In 
the associative mechanism, bond formation between the attacking nucleophile and the γ-
PO4 precedes the leaving of the ADP moiety (Cleland and Hengge 1995). Current 
enzymatic studies of tyrosine kinases, however, instead favor a dissociative mechanism, 
in which the reaction order at this stage is reversed and the ADP moiety leaves first. In 
this mechanism, the nucleophilicity of the phosphate acceptor is less important (Cleland 
and Hengge 1995; Cole, Courtney et al. 2003; Shen, Hines et al. 2005). In fact, a neutral 
Tyr sidechain seemed to be a better substrate than the negatively charged tyrosinate in 
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studies of the Csk tyrosine kinase (Kim and Cole 1997; Kim and Cole 1998) and the role 
of Asp1 was hypothesized to be stabilization of a preferred rotamer of the tyrosine 
hydroxyl to facilitate the reaction process (Adams 2001).  
Catalytic activity of tyrosine kinases is tightly regulated in cells, and EGFR has 
been used as a model system for studying the activation of ErbB family kinases. Unlike 
most tyrosine kinases, although EGFR TKD contains a tyrosine in the activation loop, 
phosphorylation of this tyrosine is not required for EGFR kinase activation (Tice, 
Biscardi et al. 1999). Zhang et al. (Zhang, Gureasko et al. 2006) have shown that the 
EGFR kinase domain is activated through the formation of an asymmetric homodimer 
(Figure 1.2C) – in which the C-lobe of the activating kinase domain (yellow in Figure 
1.2C) interacts with the N-lobe αC region of the activated kinase (blue in Figure 1.2C), 
inducing allosteric alterations and stabilizing the latter in the active conformation. 
Mutations in the crystallographically observed interface between the activating kinase 
and the activated kinase disrupt dimer formation and EGFR activation. In addition, the 
juxtamembrane region of EGFR is now known to contribute to stabilization of the 
asymmetric dimer shown in Figure 1.2C by wrapping around the C-lobe of the activating 
kinase domain as a so-called juxtamembrane ‗latch‘  (Jura, Endres et al. 2009; Red 
Brewer, Choi et al. 2009).  A similar allosteric activation mode through asymmetric 
dimerization has also been described for ErbB4 (Qiu, Tarrant et al. 2008). 
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Figure 1.2: Structural features of tyrosine kinase domain. (A) Overall structure of tyrosine kinase domain in 
the active conformation (PDB 1IR3). Dark red: ATP; Orange: activation loop; Blue: peptide substrate 
(tyrosine sidechain is shown); Green: magnesium ion. (B) Close view of TKD active site. (C) Asymmetric 
dimer of EGFR TKD (adapted from (Zhang, Gureasko et al. 2006)). Yellow: activating kinase; Light blue: 
activated kinase. 
 
1.1.5 ErbB3, a Heretical Kinase with Changes at Conserved Catalytic Residues in 
TKD 
As mentioned in the previous section, the ErbB3 kinase domain harbors amino acid 
substitutions at two key conserved sites. First, an Asn (N815) replaces the conserved 
catalytic Asp in the HRD motif (Asp1 in Figure 1.2B) that lies near the γ-PO4 of ATP 
and the side chain hydroxyl of the substrate tyrosine. Other than being important for full 
catalytic activity in other kinases, the exact function of this aspartate is the subject of 
much debate. Site-directed mutagenesis of this aspartate in protein kinase A (Gibbs and 
Zoller 1991) and the Csk tyrosine kinase (Cole, Grace et al. 1995) substantially reduces 
(but does not abolish) kinase activity. Moreover, a D813A EGFR mutant is still capable 
of mediating EGF-induced DNA synthesis (suggesting some residual kinase activity), 
whereas a K721R (kinase-dead) EGFR mutant cannot (Coker, Staros et al. 1994). These 
findings argue that replacement of this Asp with Asn815 in ErbB3 does not necessarily 
imply an absence of kinase activity.  
The second amino acid substitution in ErbB3 TKD occurs at the conserved Glu 
site in the C helix (Glu-C in Figure 1.2B), which in other kinases forms a salt bridge 
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with lysine in the VAIK motif and contributes to stabilization of the ATP binding site in 
the active conformation. This Glu is replaced in ErbB3 by a histidine (H740). However, 
the effect of mutating this residue is not well understood. It should also be noted that the 
sequence of ErbB3 in the αC helix region is very different from that in other kinases, so 
that an alternative structural solution might exist to stabilize the active conformation. 
Apart from these two mutations, other conserved residues near the ATP binding pocket 
thought to be crucial for kinase activity are all ―intact‖ in ErbB3. 
Following the initial cloning of ErbB3, and realization that its kinase domain 
harbors these unusual differences from ‗canonical‘ protein kinases, several early 
biochemical studies investigated ErbB3 kinase activity and concluded qualitatively that it 
is kinase-inactive (Guy, Platko et al. 1994; Sierke, Cheng et al. 1997). Insect cell-
expressed recombinant ErbB3 intracellular domain was reported neither to bind ATP nor 
to become autophosphorylated in vitro (Sierke, Cheng et al. 1997). On the other hand, 
full-length ErbB3 protein expressed in insect cells could be affinity labeled with an ATP 
analogue through crosslinking (Guy, Platko et al. 1994), but was autophosphorylated 
only to a very small extent that was not increased by addition of ligand neuregulin – and 
was therefore ascribed to ‗background‘ trans-phosphorylation by endogenous insect cell 
kinases (Guy, Platko et al. 1994). Based on these findings, the prevailing view in the 
literature is that the ErbB3 kinase domain is an inactive ‗pseudokinase‘ (Citri, Skaria et 
al. 2003; Boudeau, Miranda-Saavedra et al. 2006). These initial studies should be 
interpreted with caution, however. The in vitro studies of the ErbB3 intracellular domain 
only investigated diluted protein in solution (Sierke, Cheng et al. 1997) – whereas the 
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EGFR precedent argues that dimerization is likely to be required for kinase activation.  
Moreover – although the authors did not realize this at the time – neuregulin binding 
does not induce ErbB3 homodimerization (Berger, Mendrola et al. 2004), so the cellular 
studies of full-length ErbB3 never actually subjected the protein to a treatment that may 
activate its kinase activity. Therefore, these prior studies failed to investigate ErbB3 
kinase activity under conditions where activity (if present) would be manifest (i.e. 
following dimerization or oligomerization).  Nonetheless, all proposed signaling 
mechanisms involving ErbB3 have assumed that it has no kinase activity. 
1.1.6 Summary 
ErbB3 is a unique member of the ErbB family RTKs. It contains an atypical kinase 
domain and an extracellular domain that exclusively forms heterodimers with other 
ErbBs. ErbB3 plays an important role in the development of cancers, especially when 
partnered with ErbB2. In oncology, current ErbB3 targeting therapeutic strategies only 
focus on developing specific antibodies for ErbB3 ectodomain. On the other hand, the 
ErbB3 kinase domain has not been pursued therapeutically as it is unclear whether 
ErbB3 is a functional kinase. 
Other than the observation of amino acid alterations in ErbB3 TKD, few 
experimental studies have attempted to address the question of whether ErbB3 is able to 
function as a kinase, especially under the conditions similar to those necessary for other 
ErbB kinases to become activated. An increasing number of studies have discovered that 
many of the presumed-inactive pseudokinases actually retain significant activity. 
17 
 
Therefore, it is inappropriate to assume that ErbB3 is ‗kinase-dead‘ simply based on these 
observations. If ErbB3 is an active kinase, targeting this activity would offer a novel and 
very promising treatment for ErbB2/ErbB3 expressing breast cancers that are resistant to 
Herceptin and Tykerb. My study aims to investigate, using updated knowledge of ErbB 
kinases, whether ErbB3 kinase retains catalytic activity and to understand the role of 
ErbB3 TKD in cell signaling.  
1.2 In vitro Characterization of the Enzymatic Activity of ErbB3 TKD  
1.2.1 Autophosphorylation of the Purified ErbB3 Intracellular Domain 
N-terminally 6xHis-tagged ErbB3 intracellular domain (ErbB3-ICD, residues 665-1323) 
and isolated tyrosine kinase domain (ErbB3-TKD, residues 665-1001) were expressed in 
baculovirus-infected Sf9 cells and proteins were purified as described in Experimental 
Procedures. Neither ErbB3-ICD nor ErbB3-TKD showed any autophosphorylation 
activity when incubated with only Mg
2+
 and ATP in solution, consistent with previously 
published studies (Sierke, Cheng et al. 1997). However, robust tyrosine 
autophosphorylation could be seen in anti-phosphotyrosine Western blots (Figure 1.3A) 
when lipid vesicles containing DOGS-NTA-Ni (1, 2-dioleoyl-sn-glycero-3-([N(5-amino-
1-carboxypentyl)iminodi-acetic acid] succinyl) nickel salt) were added to the reaction 
system, allowing 6xHis-tagged ErbB3-ICD to be clustered onto the vesicle surfaces 
(Figure 1.3A, two right-most lanes). This method was used previously to promote 
assembly of 6xHis-tagged signaling molecules on membrane surfaces for several 
receptors (Shrout, Montefusco et al. 2003), and was crucial for activity in earlier studies 
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of EGFR kinase activation by Kuriyan and colleagues (Zhang, Gureasko et al. 2006). 
Autophosphorylation is also dependent on the addition of Mn
2+
 or Mg
2+
 ions (Figure 
1.3B), with Mn
2+
 slightly preferred. Consistent with the fact that ErbB3 phosphorylation 
sites are concentrated in the C-terminal tail, removing this region to give ErbB3-TKD is 
accompanied by a loss of detectable autophosphorylation. 
To confirm that the autophosphorylation shown in Figure 1.3A arises from 
ErbB3-ICD protein, and not from other contaminating kinases, we assessed the ability of 
a K723M-mutated form of the protein to autophosphorylate under the same conditions. 
This conserved Lys is important for ATP-binding to the tyrosine kinase domain, and 
mutation of the analogous residue is well known to abolish the activity of many kinases, 
including EGFR (Honegger, Dull et al. 1987; Zhang, Gureasko et al. 2006). As shown in 
the second lane of Figure 1.3C, the K723M mutation greatly diminishes the degree of 
ErbB3-ICD autophosphorylation. However, the K723M-mutated ErbB3-ICD protein is 
trans-phosphorylated robustly on its C-terminal tail when the 6xHis-tagged isolated 
ErbB3-TKD is added, as shown in lane 3 of Figure 1.3C. On the other hand, the ability to 
trans-phosphorylate ErbB3-ICD is substantially diminished when the added ErbB3-TKD 
also harbors a K723M mutation (Lane 4 in Figure 1.3C and lane 5 of Figure 1.3D left). 
Similarly, a K723R mutation also disrupts the kinase activity of ErbB3-TKD (lane 4 of 
Figure 1.3D right). The ErbB3 TKD contains a tyrosine (Y849) in its activation loop.  To 
test the hypothesis that phosphorylation of this tyrosine activate kinase activity, Y849 
was mutated to Glu to mimic the negatively charged phosphotyrosine. This mutation 
impairs the ability of ErbB3-TKD to trans-phosphorylate the ICD‘s C-terminal tail (Lane 
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6 in Figure 1.3D left), arguing against this hypothesis, but nonetheless suggesting some 
role for this tyrosine in regulation of ErbB3‘s kinase activity. In addition, the Ala 
substitution of V836 at the beginning of the activation loop also showed diminished 
kinase activity (Lane 5 in Figure 1.3D right) and its implication will be discussed in 
sections 1.3 and 1.4. We also asked whether reintroduction of the Asp at the position 
occupied by the proposed catalytic base in other kinases (in the N815D mutant) can 
increase the trans-phosphorylation activity of ErbB3-TKD. As shown in Lane 7 of Figure 
1.3D (left), the N815D mutation did not have a significant activating effect, consistent 
with a previous report (Prigent and Gullick 1994).  
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Figure 1.3: Autophosphorylation of the ErbB3 Intracellular Domain in vitro. (A) ErbB3-ICD 
autophosphorylation monitored by immunoblotting with anti-phosphotyrosine antibodies. ErbB3-ICD at 3 
M was incubated at 25˚C in 100 mM MOPS, pH 7 containing 2 mM MnCl2, 5 mM MgCl2, 200 mM NaCl, 
5 % glycerol, and 0.1 mM DTT. Lane 1 contained molecular weight markers. For lane 2, 125 M 
phospholipid (in vesicles) containing 10% (mole/mole) DOGS-NTA-Ni was added to 3 M ErbB3-ICD. 
Lanes 3 and 4 represent duplicate samples in which 1 mM ATP and control vesicles (lacking DOGS-NTA-
Ni) were added to 3 M ErbB3-ICD. In lanes 5 and 6, 1 mM ATP plus DOGS-NTA-Ni vesicles were 
added, and significant autophosphorylation was seen. Reactions were stopped after 30 mins by adding 
50 mM EDTA and SDS-PAGE gel-loading buffer. Samples were subjected to SDS-PAGE and 
immunoblotting with anti-phosphotyrosine antibodies (upper panel) and an anti-pentahistidine antibody 
(lower panel) for loading control. (B) Dependence on divalent cation concentration of ErbB3-ICD 
autophosphorylation. Purified ErbB3-ICD (3 M) was incubated for 30 minutes in 100 mM MOPS pH 7.4, 
containing 1 mM ATP, 125 M phospholipid (in vesicles) with 10 % (mole/mole) DOGS-NTA-Ni, and the 
noted concentrations of MnCl2 or MgCl2. (C)  For lane 1, 3 M ErbB3-ICD was allowed to 
autophosphorylate as in lanes 5 and 6 of (A). K723M-mutated ErbB3-ICD was treated identically for lane 2, 
and little autophosphorylation was observed. Autophosphorylation of K723M-mutated ErbB3-ICD was 
recovered when the wild-type isolated ErbB3-TKD
665-1001
 was added at 6 M (lane 3), and to a significantly 
lesser extent when K723M-mutated ErbB3-TKD
665-1001
 was added (lane 4). Thus, the isolated ErbB3-TKD 
can phosphorylate ErbB3-ICD in trans. (D) The ability of wild-type and mutated ErbB3-TKD
665-1001
 to 
trans-phosphorylate ErbB3-ICD was compared as described in the text. 
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Although these results demonstrate that ErbB3 is capable of catalyzing 
phosphoryl-transfer, we found that its catalytic efficiency is substantially lower than seen 
for EGFR activated in a similar manner. We have not been able to detect significant 
phosphorylation of added poly(Glu:Tyr) substrates or of short peptides modeled on 
phosphorylation sites within ErbB3 or ErbB2. Experiments in which the incorporation of 
32
P into the ErbB3 intracellular domain was used to monitor rates of trans-
phosphorylation (Figure 1.4) suggested that ErbB3-TKD phosphorylates ErbB3-ICD at a 
rate that is about 1000 fold slower than that seen for EGFR under similar experimental 
conditions. Nonetheless, the experiments in Figure 1.3 show that ErbB3 does contain an 
active kinase domain. 
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Figure 1.4: Quantitation of 
32
P incorporation into ErbB3-ICD by the kinase domains from ErbB3 or EGFR. 
A final concentration of 3 μM wild-type ErbB3-TKD or EGFR-TKD was co-incubated with 6 μM 6xHis-
tagged ErbB3-ICD (K723M) as substrate in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% glycerol, 
containing 0.1 mM DTT, 5 mM MgCl2, 2 mM MnCl2, 100 μM ATP (with 3 μCi [γ-32P]ATP) and 100 μM 
lipid (vesicles containing 10% DOGS-NTA-Ni with 90% DOPC). Reaction mixtures were incubated at 
room temperature for the times listed, and reactions were stopped by adding EDTA to a final concentration 
of 50 mM. Samples were spotted onto phosphocellulose paper to immobilize protein. After a series of 
washes, 
32
P incorporation was measured by scintillation counting. Mean range of variation are plotted from 
at least two independent experiments. 
32
P incorporation catalyzed by ErbB3-TKD occurred at 
approximately 209 cpm per minute (5,087 in 25 min; 10,698 in 50 min). 
32
P incorporation catalyzed by 
EGFR-TKD was clearly saturating (or depleting substrate) by 25 min. On the basis of the 1-min time point, 
we estimate a maximum incorporation rate of 198,575 cpm per minute, suggesting a rate that is ∼940-fold 
higher than that for ErbB3-TKD. 
 
1.2.2 ErbB3 TKD Fully Retains ATP Binding Ability 
Having detected kinase activity with our ErbB3 proteins, we next investigated the ATP-
binding properties of ErbB3-TKD, since previous analyses have yielded conflicting 
results (Guy, Platko et al. 1994; Sierke, Cheng et al. 1997). We used mant [2'-(3')-O-(N-
methylanthraniloyl)]-ATP, a fluorescent analogue of ATP, for direct binding studies. As 
shown in Figure 1.5A, a solution of 1 M mant-ATP (plus 5 mM MgCl2) does not have 
significant fluorescence when excited at 280 nm. However, following addition of ErbB3-
TKD at 3 M there is a significant peak centered at 448 nm that reflects fluorescence 
resonance energy transfer (FRET) from tryptophans and/or tyrosines in the protein to the 
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mant-ATP. The peak at 448 nm is absent without mant-ATP, and the observed FRET 
requires that ErbB3-TKD, MgCl2, and mant-ATP are all present in the sample (Figure 
1.5B). Moreover, FRET is substantially diminished when 20 M ATP is added (a 20-fold 
excess over mant-ATP), which should saturate the nucleotide-binding site in the kinase. 
These results argue that the ErbB3 kinase domain does indeed bind ATP.  
To estimate the affinity of this binding, we monitored FRET from the kinase to 
mant-ATP upon titration of ErbB3-TKD into a solution containing 0.6 M mant-ATP 
plus 5 mM MgCl2. A simple hyperbolic binding curve was observed, as shown in Figure 
1.5C, which suggested a KD value of 1.1 M for Mg
2+
/mant-ATP binding to ErbB3-TKD. 
This is lower than KD values measured for Mg
2+
/ATP binding to EGFR (Cheng and 
Koland 1998) or protein kinase A (Iyer, Garrod et al. 2005). It is also smaller than 
apparent KM values for (Mg
2+
 or Mn
2+
) ATP measured for EGFR (Qiu, Tarrant et al. 
2009), ErbB2 or ErbB4 (Qiu, Tarrant et al. 2008). Consistent with the significant 
reduction in autophosphorylation activity seen for the K723M mutant in Figure 1.3, 
substitution of this lysine with methionine also greatly diminishes mant-ATP binding to 
ErbB3-TKD (Figure 1.5C). We have also performed some preliminary mant-ATP 
binding experiments with the K723R and V836A mutants of ErbB3 TKD, and the results 
suggested that the K723R mutant retains ATP binding affinity, while the V836A 
mutation disrupts ATP binding  (Figure 1.5D).  
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Figure 1.5: Mant-ATP Binding to ErbB3-TKD
648-1001
. (A)  Fluorescence emission spectra (with excitation 
at 280 nm) are shown for 1 M mant-ATP (plus 5 mM MgCl2) in the absence of ErbB3-TKD (black) and 
with 3 M added ErbB3-TKD648-1001, illustrating FRET between the protein and bound mant-ATP. (B) 
Fluorescence emission of 1 μM mant-ATP at 450 nm under different conditions (with excitation at 280 nm). 
No significant protein-to-mant FRET is seen for 1 M mant-ATP alone, or any pairwise combination of 
1 M mant-ATP, 5 mM MgCl2, and 3 M ErbB3-TKD
648-1001
. However, when all three are added together, 
significant fluorescence emission is seen at 450 nm, signifying mant-ATP binding. The FRET signal is 
greatly reduced by adding 20 M ATP to saturate the nucleotide-binding site in the kinase (far-right 
column), indicating that FRET reflects specific binding to the ATP-binding site. (C)  Titration of ErbB3-
TKD
648-1001 
into a solution of 0.6 M mant-ATP containing 5 mM MgCl2 causes an increase in fluorescence 
emission from mant-ATP at 450 nm (via FRET from the protein to which it is bound). The resulting 
hyperbolic binding curves were fit to a simple binding equation, yielding a best-fit KD value of 1.1 M for 
wild-type ErbB3-TKD. A K723M mutation variant greatly diminished (but did not abolish) mant-ATP 
binding. (D) Mutating V836 in ErbB3-TKD
665–1001
 disrupts mant-ATP binding. Samples containing buffer 
alone or mutated ErbB3-TKD at 10 μM were incubated alone (fourth set of bars), with 5 μM mant-ATP 
(third set of bars), with 5 μM mant-ATP plus 10 mM MgCl2 (first and second sets of bars), or with 5 μM 
mant-ATP, 10 mM MgCl2 plus 500 μM ATP (fifth set of bars). Assays were performed in 20 mM Tris pH 
8.0, 200 mM NaCl, 5% glycerol. Fluorescence measurements were taken in triplicate using a Tecan 
SAFIRE II plate reader, with excitation wavelength of 340 nm and emission wavelength of 450 nm (10-nm 
bandwidth for both). The K723R mutant binds mant-ATP with an affinity similar to that seen for wild-type 
protein and shows a substantial increase in fluorescence emission from mant-ATP that can be competed 
away by addition of excess ATP. By contrast, the V836A mutant displayed little evidence of binding, 
consistent with the loss of the ability of V836A-mutated ErbB3-ICD to autophosphorylate as assessed in 
immunoblotting assays. Note that the first and second sets of bars are experimental repeats. 
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1.2.3 Inhibitor Profiling of ErbB3 Kinase 
We next investigated whether currently available kinase inhibitors (especially those 
targeting ErbB kinases) can inhibit the kinase activity of ErbB3. This study serves two 
purposes: 
1) Since these inhibitors all target the ATP binding pocket of kinases, an inhibitor 
sensitivity ‗profile‘ will provide one view of the similarity between the ATP 
binding pocket of the ErbB3 TKD and that of other kinases (such as EGFR) using 
these inhibitors as probes. 
2) The screen could potentially identify inhibitor(s) that can preferentially inhibit 
ErbB3 kinase but not other ErbB kinases. Such inhibitor could be applied in 
cellular studies to examine the role of ErbB3 kinase. 
We first examined whether the current FDA-approved EGFR-specific inhibitors 
(gefitinib, erlotinib and lapatinib) can effectively inhibit ErbB3 kinase. Figure 1.6A 
shows that, at low micromolar concentration, none of the three inhibitors blocks the 
kinase activity of ErbB3, whereas all of them completely inhibit EGFR kinase. This 
result is not surprising since (1) these three inhibitors are optimized for EGFR and (2) the 
ErbB3 kinase is more homologous to ErbB4 kinase, which is also a much weaker binder 
of these inhibitors (Wood, Truesdale et al. 2004). 
Next, using small inhibitor libraries containing commercially available ATP-
competitive kinase inhibitors, we examined the inhibition profile of ErbB3 kinase, to 
compare it with that of EGFR kinase. Since no available inhibitor has been optimized for 
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ErbB3 kinase, these experiments were performed at a higher concentration of inhibitor 
(50 µM) and lower concentration of ATP (100 µM) in order to identify inhibitor 
candidates that are likely to have relatively weak binding of ErbB3 kinase. The results 
showed that, although the EGFR and ErbB3 kinases share fairly similar inhibition 
profiles, most inhibitors that did block their activities appear to have less potency towards 
ErbB3 than EGFR, represented by a smaller degree of ErbB3 inhibition in this qualitative 
assay. In addition, some of the EGFR kinase inhibitors failed to block ErbB3 activity at 
all. The work of our collaborators in the laboratory of Kevan Shokat at U.C.S.F. has 
shown similar results. Therefore, we conclude from this study that, although the overall 
ATP binding site of ErbB3 TKD is structurally similar to that of EGFR kinase, it is 
targeted less effectively by current kinase inhibitors. One reason for this may be the 
relatively stronger ATP binding of ErbB3 TKD compared to other kinases as determined 
in our mant-ATP assay. Another reason could be that the structural configurations of 
ErbB3 kinase (and its most populated states in the conformational ensemble) are weaker 
binders for these inhibitors. 
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Figure 1.6: Inhibitor Profiling of ErbB3 Kinase. (A) Western blot analysis to assess the effect of EGFR or 
EGFR/ErbB2 inhibitors on ErbB3-TKD activity (left) and EGFR-TKD activity (right). ErbB3-ICD (0.3 μM) 
was mixed with 0.3 μM ErbB3-TKD (left) or 0.3 μM EGFR-TKD (right) in 1 mM ATP (except in the first 
lane), 5 mM MgCl2, 2 mM MnCl2, 10 μM lipid (10%NTA-NiDOGS + 90%DOPC in vesicles), 20 mM 
Tris-HCl pH8.0, 200 mM NaCl, 5% glycerol and 0.1 mM DTT for 1 hr (left) or 1min (right) at 25 °C. 
Phosphorylation was monitored by Western blotting with pY20 antiphosphotyrosine (Upper) and anti-His5 
antibody for normalization (Lower). To assess inhibitor specificity, experiments were performed in the 
presence of 4 μM lapatinib (L), 4 μM gefitinib (G), 4 μM erlotinib (E), or without inhibitor (DMSO only: 
―-‖). All three inhibitors blocked EGFR activity, but left trans-phosphorylation by ErbB3-TKD unaffected.   
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(B) Western blot analysis to assess the effect of a commercially available kinase inhibitor library (EMD#1) 
on ErbB3 kinase activity (left) and EGFR kinase activity (right). 1 μM ErbB3-ICD or 0.1 μM EGFR-ICD is 
incubated with 50 μM inhibitor and 100 μM ATP in kinase assay buffer (same as in A) for 1 hour (for 
ErbB3) or 5 minutes (for EGFR) at 25 °C. Reactions were quenched with EDTA (100 mM final 
concentration) and 2 μl of each sample was spotted onto nitrocellulose paper. After drying, phosphorylation 
was monitored by Western blotting with pY20 anti-pTyr antibody and corresponding anti-mouse HRP 
secondary antibody. Samples in the first column of each blot (8 samples on the left) represent kinase 
reaction without inhibitor (DMSO only).  Kinase inhibitors in the EMD#1 library are listed in Appendix 1. 
 
1.3 Structural Characterization of ErbB3 Kinase Domain by X-ray 
Crystallography 
To gain insight into how the ErbB3 tyrosine kinase domain retains activity despite 
substitutions at key residues, we determined its crystal structure. Crystals of ErbB3-TKD
 
grew only in the presence of 5 mM MgCl2 and the non-hydrolyzable ATP analogue 
adenylyl-imidodiphosphate (AMP-PNP), and diffracted X-rays to 2.8 Å resolution (Table 
1.1). The structure was solved by molecular replacement using an inactive EGFR TKD 
structure as search model. The asymmetric unit contains two ErbB3-TKD molecules, 
which are almost identical to one another and pack in the crystal lattice in an N-lobe to 
N-lobe, C-lobe to C-lobe manner (Figure 1.7). 
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Table 1.1:  ErbB3 TKD crystallographic statistics (molecular replacement). 
 ErbB3 TKD  
Data collection APS (GM/CA CAT) 
Space group C2 
  
    a, b, c (Å),  (˚) 193.4, 48.0, 82.2,  = 108.1˚ 
Resolution (Å) 50.00 - 2.80 (2.85-2.80) * 
Rsym or Rmerge 0.083 (0.499) 
I / σI 17.1 (2.2) 
Completeness (%) 90.0 (55.3) 
Redundancy 6.3 (3.4) 
  
Refinement  
Resolution (Å) 50.00 – 2.80 
No. reflections 14406 
Rwork / Rfree 25.2/28.5 
  
Model  
Protein amino acids aa A680-728, 732-844, 854-959 
aa B680-711, 713-729, 732-845, 854-959 
No. atoms 4316 
    Protein 4245 
    Ligand/ion 64 
    Water 7 
R.m.s. deviations  
    Bond lengths (Å) 0.006 
    Bond angles (˚) 1.099 
*Values in parentheses are for highest-resolution shell. 
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Figure 1.7: Cartoon representation of the crystal packing of ErbB3-TKD. The green structure is molecule A 
in the asymmetric unit, and the red structure is molecule B. These associate in the crystals through N-lobe 
mediated interactions. In addition, interaction partners in the crystal are shown for molecule B (red) that 
associate through alternative N-lobe mediated (dark blue) and C-lobe mediated (cyan) contacts. The 
packing of ErbB3-TKD molecules in our crystals appear to be the same as those described and discussed in 
detail by Jura et al. (Jura, Shan et al. 2009). 
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As shown in Figure 1.8A, the overall structure of ErbB3-TKD closely resembles 
that of the inactive conformation of the EGFR kinase (Zhang, Gureasko et al. 2006), and 
in turn that of the inactive ErbB4 and Src kinase domains (Zhang, Gureasko et al. 2006; 
Qiu, Tarrant et al. 2008). Although reduced in length as described below, the C helix of 
ErbB3-TKD is displaced away from the active site, in the ‗out‘ position typically seen in 
structures of inactive kinases (Huse and Kuriyan 2002). The activation loop of ErbB3-
TKD also retains the characteristic short -helix that abuts the C helix in inactive EGFR 
and ErbB4 (green in Figure 1.8A), and is the site of key mutations that activate EGFR in 
non-small cell lung cancer (NSCLC) (Sharma, Bell et al. 2007). One particularly notable 
difference between ErbB3-TKD and the other ErbB kinases is the length of the C helix, 
the amino-terminal half of which (~1.5 turns in EGFR) is unraveled in ErbB3-TKD. This 
region forms a well-defined loop (residues 732-739) in ErbB3-TKD that appears to be 
anchored by backbone-mediated interactions with the 4/5 loop and the projection of 
the F734 side-chain into a hydrophobic pocket formed largely by side-chains from 3 
(I725), 5 (L764), C (M741), and the activation loop (L839 and L840) (Figure 1.8B). 
Consistent with our mant-ATP binding studies shown in Figure 1.5, we could see 
clear electron density for both AMP-PNP and Mg
2+
 in the ErbB3-TKD structure (Figure 
1.8C). The bound Mg
2+
 ion is coordinated by the side-chains of N820 and D833 (from 
the DFG motif), plus the - and -phosphates of AMP-PNP. The -amino group of the 
highly conserved K723 residue (in strand 3) interacts with both the -phosphate of 
AMP-PNP and the D833 side-chain, thus playing a key role in nucleotide binding as seen 
for inactive EGFR, and indicated by the substantially reduced kinase activity (Figure 1.3) 
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and mant-ATP binding (Figure 1.5) in the K723M variant of the ErbB3 intracellular 
domain or TKD. 
 
 
35 
 
Figure 1.8: Crystal structure of ErbB3-TKD. (A) Cartoon representations are shown for ErbB3-TKD
665-1001
 
(left: red) EGFR-TKD in its inactive configuration (Zhang, Gureasko et al. 2006) from PDB code 2GS7 
(middle: cyan), and EGFR-TKD in its active configuration with a bound bisubstrate analogue of ATP and 
peptide (Zhang, Gureasko et al. 2006) from PDB code 2GS6 (right: grey). Bound AMP-PNP and Mg
2+
 ions 
are shown in spheres and marked, with only the nucleotide portion of the bisubstrate analogue shown for 
active EGFR. The C helix is colored blue in each structure, and is denoted as being in the ‗out‘ position in 
ErbB3 and inactive EGFR, and the ‗in‘ position in active EGFR. The short -helix in the activation loop of 
ErbB3 and inactive EGFR is colored green. H740 in the C helix of ErbB3 replaces a conserved glutamate 
(E738 in EGFR), and is shown in stick representation. N815 (which replaces the conserved catalytic base 
D813) is also marked and shown in stick representation. -strands in the N-lobe are also labeled. (B) Close-
up view of the unraveling of αC in ErbB3 TKD structure. The protein sequence (residues 732-739) 
equivalent to the amino-terminal half of the EGFR αC forms a well-defined loop in ErbB3-TKD that 
appears to be anchored by backbone-mediated interactions with the β4/β5 loop and the projection of the 
F734 side-chain into a hydrophobic pocket formed largely by side-chains from β3 (I725), β5 (L764), αC 
(M741), and the activation loop (L839 and L840). (C) Close-up view of Mg
2+
-AMP-PNP in the ErbB3-
TKD
665-1001
 active site, with electron density shown as a 2Fo-Fc map calculated at 1.8 with phases from a 
model into which nucleotide had not been placed. Coordination of the bound Mg
2+
 ion by the side-chains of 
N820 and D833 (from the DFG motif), plus the - and -phosphates of AMP-PNP is depicted. The 
position of N815 (close to the -phosphate) is also shown. The side-chain of K723 (in strand 3), which 
interacts with the -phosphate of AMP-PNP and the D833 side-chain is occluded by the Mg2+ ion in this 
view, and cannot be seen. (D)  Close-up view of the short -helix seen in the activation loop of ErbB3-
TKD (red) and inactive EGFR-TKD (cyan), with the two kinase superimposed. Mutations at L834 or L837 
in EGFR activate the receptor in NSCLC. The side-chains of these residues overlay very well with V836 
and L839 in the inactive-like ErbB3-TKD structure, and interact with the hydrophobic pocket that 
contributes to stabilization of the C helix in the ‗out‘ position. 
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The activation loop configuration seen in ErbB3-TKD closely resembles that of 
the inactive EGFR and ErbB4 kinase domains (Zhang, Gureasko et al. 2006; Qiu, Tarrant 
et al. 2008), and is quite distinct from that seen for active kinases (Huse and Kuriyan 
2002). The short -helix in the activation loops of EGFR and ErbB4 contains several 
aliphatic side-chains (L834, L837 and L838 in EGFR) that participate in interactions with 
a hydrophobic pocket formed by side-chains from the -sheet in the N-lobe and the C 
helix. Mutations at L834 and L837 (L834R and L837Q) are known to activate EGFR in 
some NSCLC cases (Sharma, Bell et al. 2007) by disrupting these interactions, and 
appear to be oncogenic driver mutations in this cancer.  ErbB4 can be activated similarly 
(Qiu, Tarrant et al. 2008). Moreover, mutating residues that contribute to the hydrophobic 
pocket into which these aliphatic side-chains project can activate EGFR in vitro (Choi, 
Mendrola et al. 2007). In ErbB3, a conserved VLL motif (V836, L839, L840) in the short 
activation loop helix makes a very similar set of interactions, apparently stabilizing the 
‗inactive-like‘ position of the C helix. As shown in Figure 1.8D, residues V836 and 
L839 in ErbB3 overlay almost exactly with L834 and L837 in EGFR (key sites of 
activating NSCLC mutations). To investigate whether similar mutations in ErbB3 can 
potentially disrupting this inactive-like conformation – we made V836R and L839Q 
mutations in ErbB3 (parallel to the NSCLS mutations in EGFR), and their effects on 
cellular signaling will be examined in the next section. Unfortunately, recombinant 
ErbB3 TKD protein containing either of the mutations does not remain monomeric in 
solution but form aggregates during purification, therefore its effect on kinase activity 
cannot be measured directly by in vitro kinase assay. However, properties of a similar 
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V836A mutant of ErbB3 TKD suggest that mutating this hydrophobic VLL motif may 
likely disrupt this conformation, as it displays compromised ATP binding ability (Figure 
1.5D) and kinase activity (Figure 1.3D). 
In addition to replacement of the proposed catalytic base with an asparagine in 
ErbB3 (N815), one of the notable sequence alterations that led to the assignment of 
ErbB3 as a pseudokinase is replacement of the conserved glutamate in the C helix with 
a histidine (H740). Interestingly, this histidine forms a predicted hydrogen bond with the 
carbonyl oxygen of G835 in the ErbB3 DFG motif. Recent indications of the importance 
of the conformational dynamics of the DFG motif (Jura, Shan et al. 2009) suggest that 
this interaction could be relevant for controlling ErbB3 kinase activity. In the inactive 
EGFR TKD, E738 does not make an equivalent predicted hydrogen bond, but may 
interact with the side-chain of K836 that follows the DFG motif in EGFR. 
The crystal structure of ErbB3 has revealed important structural features of ErbB3 
TKD and its binding mode to ATP. However, it is unclear whether the catalytic activity 
observed in our in vitro assays is mediated by this conformation, since it closely 
resembles the inactive conformation of EGFR kinase. On the other hand, since ErbB3‘s 
enzymatic activity is much lower than EGFR, it is possible that this limited catalysis of 
the phosphoryl transfer reaction could be mediated through this unusual conformation. 
Indeed, QM/MM simulations by the Radhakrishnan lab at U. of Penn. have depicted a 
possible reaction pathway for ErbB3 to catalyze tyrosine phosphorylation in such a 
conformation (Figure 1.9) (Shi, Telesco et al.). The estimated activation energy (Ea) for 
phosphoryl transfer is 23 kcal/mol for ErbB3 kinase in this conformation, higher than the 
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16 kcal/mol activation energy for EGFR kinase in the active conformation, consistent 
with the fact that ErbB3 is a relatively weaker kinase. At this point, we do not have 
evidence to support or disregard the possibility that alternative conformation(s) of ErbB3 
TKD contribute to its catalytic activity. 
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Figure 1.9: QM/MM simulations of phosphoryl transfer of ErbB3 and EGFR kinases (Shi, Telesco et al. 
2010). Schematic of the phosphoryl-transfer pathway in (A) EGFR-TKD and (B) ErbB3-TKD, as captured 
in QM/MM simulations. Mg
2+
 ions are marked, as are the catalytic aspartates (D831 in EGFR, D833 in 
ErbB3), the proposed catalytic base in EGFR (D813), and its replacement in ErbB3 (N815). Two potential 
pathways for proton migration (concomitant with phosphoryl transfer) are marked as described in the text: 
pathway I (Red) and pathway II (Green). The distance from the substrate -OH proton to the Oδ2 oxygen of 
D813 in EGFR is labeled δI, and its distance to the O1γ oxygen of ATP is δII. (C–F) Energy changes along 
the reaction pathway in QM/MM simulations for the noted mechanisms involving pathway II (Green) or 
pathway I (Red). States correspond to ―R‖ (reactant); ―TS‖ (transition state with trigonal-bipyramidal 
geometry around Pγ); ―P‖ (product after phosphoryl transfer with proton bound to ATP O1γ); and ―P2‖ 
(product with proton transferred to ATP O2β) (C) Energy changes along the simulated ErbB3 reaction 
pathway. Symbols bounded by black squares represent the forward scan, and those bounded by gray 
squares represent the reverse scan. Only pathway II is utilized, and estimated Ea for phosphoryl transfer is 
23 kcal/mol. (D) Energy changes along the EGFR reaction pathway (active configuration) utilizing 
pathway II and the associative mechanism: Estimated Ea is 24 kcal/mol. (E) Phosphoryl transfer catalyzed 
by EGFR via the dissociative mechanism (utilizing pathway I for proton migration—via D813) has the 
lowest Ea value, at 16 kcal/mol. (F) Associative phosphoryl transfer concomitant with pathway I for EGFR 
has an estimated Ea of 24 kcal/mol. See supplementary materials of (Shi, Telesco et al. 2010) for details. 
 
1.4 Cellular Studies to Investigate the Role of ErbB3 Kinase Domain in ErbB 
Signaling 
It is unclear from the in vitro assays described above whether the weak catalytic activity 
of ErbB3 plays a physiologically relevant role in cellular ErbB signaling. Since the kinase 
activity of ErbB3 TKD is about 1000 fold weaker than that of EGFR kinase (and other 
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ErbB kinases), and upon ligand binding ErbB3 forms heterodimers with other ErbB 
family proteins (rather than homodimer), it seems plausible that ligand-induced ErbB 
autophosphorylation in cells is carried out predominantly by the other ErbB kinase in the 
heterodimer. On the other hand, even with weaker kinase activity, ErbB3 may still 
function as a kinase in cells, especially during abnormal cancer development. Indeed, a 
weak kinase activity may be sufficient for trans-phosphorylation of heterodimerization 
partners, with the higher activity levels seen for EGFR and ErbB2 only being necessary 
for the phosphorylation of downstream signaling molecules such as PLC, Shc, and other 
examples.  
In efforts to investigate the cellular role of ErbB3‘s kinase activity, we introduced 
exogenous full length ErbB3 into BaF3 and CHO cells, which lack significant 
endogenous ErbB3 expression, and investigated whether amino acid substitutions in the 
ErbB3 kinase domain affect ErbB3-dependent signaling. Among the mutations that have 
been introduced, K723M, K723R and V836A mutants show significantly compromised 
kinase activity in in vitro kinase assays (Figure 1.3D).  Whereas ATP binding to the 
K723R mutant is retained (Figure 1.5D), ATP binding to the V836A and K723M variants 
is greatly reduced (Figure 1.5C&D) – consistent with their loss of kinase activity. Two 
other mutants (V836R and L839Q) are tested here since the equivalent mutations in 
EGFR kinase disrupt the packing of the conserved hydrophobic patch in the beginning of 
activation loop (in the inactive conformation) and play oncogenic roles in NSCLC cells. 
I919R is located on the C-lobe of ErbB3, and would be predicted to impair the ability of 
ErbB3 to function as an ―activator‖ in asymmetric ErbB TKD dimers – thus disrupting 
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the ability of ErbB3 TKD to activate its dimerization partner‘s kinase domain in an ErbB 
heterodimer. 
1.4.1 Effect of ErbB3 mutations on Autophosphorylation of ErbB2/ErbB3 
Heterodimers in BaF3 Cells  
We first investigated whether ErbB3‘s kinase activity is required for ErbB 
autophosphorylation in ErbB2/ErbB3 heterodimers induced by neuregulin binding.  We 
used BaF3 cells as a ‗null‘ background for these studies, since these murine pro-B cells 
contain no detectable EGFR, ErbB2, or ErbB4 – although a low level of ErbB3 
expression can be detected at the mRNA level.  BaF3 cells are commonly used as a 
cellular background in studies of ErbB receptor properties for these reasons (Riese, van 
Raaij et al. 1995). Co-expression of full length ErbB3 protein (wildtype or mutated) and 
wildtype ErbB2 protein in BaF3 cells was achieved through transfection of pIRES 
plasmids that allow dual expression of both cDNAs. After selecting for stable cell lines 
co-expressing the desired combination of receptor variants, cells were stimulated with the 
ErbB3 ligand neuregulin1β (Nrg1β), and ligand-induced ErbB autophosphorylation was 
examined by Western blotting (Figure 1.10A&B). Tyrosine phosphorylation levels of 
ErbB2 and ErbB3 was detected using 3 different phosphotyrosine antibodies (ErbB2 
pTyr877-specific, ErbB3 pTyr1289-specific, and pan pTyr antibodies). Although the 
expression levels of ErbB2 and ErbB3 variants were clearly different in each cell line 
(bottom two blots in each panel) despite significant efforts to normalize them using 
FACS, the data strongly suggest that mutations in the ErbB3 kinase domain did not affect 
its ability to induce neuregulin-induced ErbB2 (or ErbB3) phosphorylation, clearly 
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arguing against our initial hypothesis. In fact, none of the following ErbB3 mutations 
seemed to have a substantial influence on ErbB2 (or ErbB3) phosphorylation when 
compared with wild-type ErbB3: K723M, K723R, T768G, V836A, V836R, L839Q, 
V836R/L839Q (Figure 1.10A&B), despite that the K723M, K723R and V836A 
mutations substantially impair ErbB3 kinase activity in vitro (Figure 1.3C&D) 
(aggregation of purified recombinant TKD protein prevented us from drawing reliable 
conclusions on this for the other mutants). Taken together, these data argue that ErbB3 is 
not (at least directly) the kinase responsible for ErbB autophosphorylation in the ligand-
induced ErbB2/ErbB3 heterodimers in these BaF3 cell studies. The ErbB3 I919R 
mutation is distant from the ATP binding pocket and disrupts the presumed ability of the 
C-lobe of ErbB3 to interact ErbB2‘s N-lobe to form asymmetric dimers as depicted in 
Figure 1.2C. Therefore, I919R-mutated ErbB3 will be defective in its ability to 
allosterically transactivate ErbB2 kinase in ErbB3/ErbB2 heterodimers. The lack of 
ligand-induced ErbB autophosphorylation in this cell line (Figure 1.10A) suggests that 
ErbB2‘s kinase activity is responsible for the autophosphorylation observed in the other 
cell lines carrying ErbB3 (wildtype or mutant). 
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Figure 1.10: Autophosphorylation of ErbB2 and ErbB3 in ligand-induced ErbB2/ErbB3 heterodimers in 
BaF3 cells. (A-B) BaF3 cells were stably transfected with pIRES plasmids containing both wildtype ErbB2 
and (wildtype or mutated) ErbB3 mutants, which allows constitutive co-expression of both full length 
ErbB2 and ErbB3 in the cells. Cells were selected for high ErbB expression using FACS cell sorting.  For 
detection of autophosphorylation, BaF3 cells were serum starved for 6 hours, then washed and resuspended 
in cold PBS at a density of 1x10
7
 cells/ml, and stimulated with neuregulin1β (50 ng/ml) for 10 min at 4 ˚C. 
Cells were then lysed in RIPA buffer, and all glycoproteins were pulled down with Concanavalin A beads 
(40ul beads for 10
7
 cells) in a final volume of 100ul, and samples were prepared for Western blotting with 
indicated antibodies to assess ErbB2 and ErbB3 phosphorylation. 
 
1.4.2 Mutations within the ErbB3 Kinase Domain Affect its Ability to Activate Akt 
Signaling in CHO Cells 
We next investigated the effects of ErbB3 kinase domain mutations on the ability of this 
receptor to activate Akt signaling in response to neuregulin. Indeed, ErbB3 has been 
shown to be mainly responsible for Akt activation in the ErbB2/ErbB3 heterodimer 
(Hellyer, Kim et al. 2001). We switched to CHO cells for this part of study, since the Akt 
response could not easily be observed in BaF3 cells. CHO cells are well known not to 
express endogenous EGFR (Xu, Nagarajan et al. 2011). And other ErbBs are expressed at 
very low levels (if at all) in CHO cells (Azios, Romero et al. 2001). Accordingly, parental 
CHO cells show no Akt activation response following addition of the ErbB3 ligand 
(Nrg1β) (right-most two lanes in Figure 1.11). In contrast, when transfected with 
wildtype full length ErbB3, CHO cells show robust activation of the Akt pathway in 
response to ligand stimulation (left-most two lanes in Figure 1.11), as detected with 
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antibodies specific for phosphorylated S473 of Akt (a diagnostic of Akt activation). 
Similar levels of neuregulin-dependent Akt activation were observed in CHO cells 
expressing the K723M-mutated variant of ErbB3, which we showed has dramatically 
reduced autophosphorylation activity (in Figure 1.3C&D), and a greatly reduced affinity 
for ATP (Figure 1.5C). Similarly, T768G and V836R-mutated ErbB3 variants were able 
to support neuregulin-dependent Akt activation, consistent with the results from studies 
of ErbB2 trans-phosphorylation in BaF3 cells. We also included the I919R ErbB3 variant 
as a control since this mutation is in the C-lobe of the ErbB3 kinase domain and is 
predicted to prevent it to trans-activate the other ErbB kinase in the heterodimer as 
shown in Figure 1.2C. The lack of ligand induced Akt activation in I919R mutated ErbB3 
variant suggested that Akt activation in these studies does involve formation of 
asymmetric TKD dimers, most likely in heterodimers of ErbB3 with low levels of 
endogenous ErbB2 or ErbB4 in CHO cells. Again, overall our data suggest that 
suppressing the kinase activity of ErbB3 does not significantly affect its ability to signal 
(via PI3K) to Akt in CHO cells.    
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Figure 1.11: ErbB3 mediates neuregulin induced Akt activation in CHO cells. CHO cells were transiently 
transfected with pcDNA3.1 plasmids containing full length ErbB3 (wildtype or mutant) or parental 
pcDNA3.1 plasmid as indicated. 24 hours after transfection, CHO cells were serum starved overnight, and 
then stimulated with neuregulin1β (40ng/ml) (or PBS as negative control) for 30 min. Then cells were lysed 
in RIPA buffer and subjected to Western blotting with the indicated antibodies. For the total Akt blot, the 
pAkt(S473) blot was incubated with stripping buffer after exposure to remove antibodies and was then re-
probed with Akt antibodies. 
 
Surprisingly, disrupting the hydrophobic patch that links the small -helix in the 
ErbB3 activation loop with the C helix does appear to compromise ErbB3‘s ability to 
activate Akt to some extent, as shown for ErbB3 harboring both the V836R and L839Q 
mutations (Figure 1.12 A&B). These mutations are interesting because they correspond 
structurally to the L834R and L837Q mutations in EGFR that activate EGFR‘s kinase 
and are now well known to be oncogenic driver mutations in non-small cell lung cancer 
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(Sharma, Bell et al. 2007).  Here, in ErbB3, the equivalent mutations appear to have a 
negative (rather than activating) influence on activation of Akt signaling. As shown in 
Figure 1.12, the normalized level of neuregulin-dependent Akt activation was reduced by 
~30% in cells expressing V836R/L839Q doubly-mutated ErbB3 compared with cells 
expressing wildtype or singly mutated ErbB3 in an average over four experiments. To 
further assess this effect, we performed equivalent experiments using chimeric proteins in 
which the EGFR extracellular region is fused to the (wildtype or mutated) ErbB3 
intracellular region – again in CHO cells (which lack EGFR).  As with the ErbB3 
experiments, the EGFR/ErbB3 chimera was transiently transfected into CHO cells and its 
effect on ligand-induced (in this case by EGF) Akt activation was analyzed. The basic 
observation was reproduced in this context (Figure 1.13): whereas single V836R or 
L839Q mutations did not significantly affect the ability of the EGFR/ErbB3 chimera to 
activate Akt signaling, the combined V836R/ L839Q mutations caused a significant 
decrease of Akt activation upon ligand stimulation – to approximately 40% of levels 
induced by wildtype ErbB3.   
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Figure 1.12: V836R and L839Q double mutation in ErbB3-TKD impairs its ability to activate Akt pathway 
in CHO cell. (A) Western blots of neuregulin induced Akt activation in CHO cells transfected with full 
length ErbB3 (wildtype or mutant). Transfected CHO cells were serum-starved overnight, and neuregulin 
1β (50 ng/ml final concentration) was added for 20 minutes. Cells were then lysed in RIPA buffer and 
subjected to Western blotting with the indicated antibodies. For each Akt blot, the corresponding 
pAkt(S473) blot was incubated with stripping buffer after exposure to remove antibodies and was then re-
probed with anti-Akt antibodies. Blots are representative of 4 independent experiments. (B) Quantitative 
analysis of Akt activation level (blue) and ErbB3 expression level (grey), calculated from all 4 independent 
experiments. Band intensities (ErbB3, pAkt, Akt) were determined from Western blots using ImageJ 
software. In each independent experiment, normalized Akt activation levels were calculated as the ratio of 
the pAkt(S473) and Akt band intensities. ErbB3 expression levels were also normalized by total 
(endogenous) Akt levels. Values from all 4 experiments were combined to calculate the final means and 
standard deviations. Error bars represent one standard deviation. Significance is shown as the difference of 
ligand induced Akt activation levels between CHO cells transfected with wildtype or V836R&L839Q 
double mutated ErbB3  (p < 0.05). 
  
50 
 
 
Figure 1.13: V836R and L839Q double mutation impairs the ability of an EGFR/ErbB3 chimeric protein to 
activate the Akt pathway in CHO cells. (A) Western blots of EGF-induced Akt activation in CHO cells 
transfected with an EGFR/ErbB3 chimera (wildtype or mutated). Transfected CHO cells were serum-
starved overnight, and EGF (100 ng/ml final concentration) was added for 20 minutes on ice. Cells were 
then lysed in RIPA buffer and subjected to Western blotting with the indicated antibodies. For each Akt 
blot, the corresponding pAkt(S473) blot was incubated with stripping buffer after exposure to remove 
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antibodies, and was then re-probed with anti-Akt. Each condition is represented with samples from 3 
independent experiments. (B) Quantitative analysis of Akt activation level (blue) and EGFR/ErbB3 
chimera expression level (grey), calculated from all 3 independent experiments. Band intensities 
(EGFR/ErbB3, pAkt, Akt) were determined from Western blots using ImageJ software. In each 
independent experiment, Akt activation levels were calculated as the ratio of the pAkt(S473) and Akt band 
intensities. EGFR/ErbB3 expression levels were also normalized by total (endogenous) Akt levels. Values 
from all 3 experiments were combined to calculate the final means and standard deviations. Error bars 
represent one standard deviation. Significance is shown as the difference of ligand induced Akt activation 
levels between CHO cells transfected with wildtype or V836R/L839Q doubly mutated EGFR/ErbB3 
chimera (p < 0.01). 
 
For reasons that are not clear, the V836R/L839Q double mutant also consistently 
expresses at lower levels than either full length wildtype ErbB3 or the EGFR/ErbB3 
chimera. However, the effect is smaller than a factor of two, so this is unlikely to explain 
the reduced Akt activation that we observe – which does not appear to correlate with 
receptor expression level in this range in our studies in Figures 1.11-1.13. The lack of 
dependence of Akt activation on receptor expression levels in Figure 1.11, for example, 
suggests that the amount of ErbB3 in our CHO cell studies is over-saturating in all cases. 
Indeed, the V836R or L839Q single mutants maintain normal Akt signaling ability 
despite also displaying reduced expression levels. We therefore suggest that the ErbB3 
V836R/L839Q double mutant has an intrinsic signaling defect.  Importantly, this defect is 
seen in both full length ErbB3 and the EGFR/ErbB3 chimera, despite the fact that the 
extracellular domains of ErbB3 and EGFR have disparate dimerization properties (EGFR 
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ectodomain prefers homodimer whereas ErbB3‘s only forms heterodimers), and therefore 
the composition of ligand induced ErbB dimers should be very different in these two 
cases. In the CHO cell experiments, even upon ligand stimulation the 
autophosphorylation of ErbB3 could not be detected by Western blotting (data not 
shown), again suggesting a lack of dimerization partners (eg. ErbB2) in these cells – as 
anticipated from the literature. This contrasts with the BaF3 stable cell lines described in 
Figure 1.10, which express high levels of both ErbB2 and ErbB3 and show robust ErbB2 
and ErbB3 phosphorylation upon ligand stimulation in Western blots.  
The fact that the V836R/L839Q double mutation compromises the downstream 
signaling ability of ErbB3 TKD is surprising.  This observation seems unlikely to reflect 
a simple loss of ErbB3 kinase activity, since known kinase-defective variants (K723M, 
K723R and V836A) retain the ability to activate Akt. (However, we cannot completely 
rule out the possibility that the V836R/L839Q double mutation is required to reduce 
ErbB3‘s kinase activity to a sufficiently low level to compromise its signaling in CHO 
cells. Unfortunately, we have not been able to assess the kinase activity of 
V836R/L839Q-mutated ErbB3 in vitro, since the recombinant kinase domain harboring 
this pair of mutations aggregates during purification.) Also, the reduced Akt signaling 
activity is unlikely to result from a failure of the mutated ErbB3 to trans-activate another 
ErbB receptor present at low levels in CHO cells, since this effect shall only involve the 
C-lobe of ErbB3 TKD, which should be unaffected by these mutations. Moreover, the 
V836R/L839Q double mutation in ErbB3 did not change the ligand-induced ErbB2 or 
ErbB3 autophosphorylation levels in BaF3 cells (Figure 1.10B). We therefore suggest 
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that the V836R/L839Q double mutation influences downstream Akt signaling through 
some other mechanism. If both mutations are required to disrupt the association between 
the activation loop helix and helix C in Figure 1.8A&D, they may alter the TKD 
conformation, which in turn might affect its interaction properties with downstream 
signaling proteins.  
1.5 Summary and Discussion of ErbB3 Studies  
ErbB3 has been historically considered to have an inactive kinase domain, due to amino 
acid changes at key positions when compared with ‗canonical‘ protein kinase domains. 
We have shown that the kinase domain of ErbB3 does retain significant phosphoryl 
transferase activity despite these sequence alterations, as evidenced by trans-
autophosphorylation of the purified ErbB3 intracellular region in vitro. The observed 
kinase activity appears to be about 1000-fold weaker than that seen for EGFR. The 
ErbB3 kinase domain binds ATP with a KD of approximately 1.1 M, similar to (and 
even stronger than) that reported for many other known active kinases. Using 
commercially available kinase inhibitor libraries, we have shown that ErbB3 kinase is 
poorly targeted by current inhibitors. We also describe a crystal structure of ErbB3 kinase 
bound to an ATP analogue, which resembles the inactive EGFR and ErbB4 kinase 
domains (but with a shortened C-helix). A conserved hydrophobic patch at the 
beginning of the ErbB3 activation loop, involving side-chains from a small  helix in this 
loop, appears to be responsible for holding the protein in an inactive-like conformation. 
Mutations that disrupt this hydrophobic patch in EGFR are known to destabilize such 
inactive conformation, causing hyper-activation of the kinase – and are oncogenic drive 
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mutations in NSCLC.  By contrast, equivalent mutations in ErbB3 appear to compromise 
ErbB3‘s ability to activate downstream Akt signaling in cellular studies. Thus, the ErbB3 
TKD has novel properties – beyond simply trans-activating neighboring ErbB kinases in 
ligand induced heterodimer as proposed (Jura, Shan et al. 2009). 
A key question is whether or not the kinase activity observed in vitro is sufficient 
to mediate meaningful tyrosine phosphorylation in cells. The rate of ErbB3-ICD 
autophosphorylation when clustered on vesicles containing DOGS-NTA-Ni was about 
1000 fold slower than that seen for EGFR-ICD under similar conditions, and exogenous 
peptide phosphorylation was negligible. Since the ErbB3 TKD is predicted not to form 
the same asymmetric homodimers as seen for EGFR (Zhang, Gureasko et al. 2006), this 
difference might simply reflect our failure to activate ErbB3 completely using this in 
vitro approach. Alternatively, the maximum kinase activity of ErbB3 might indeed be 
~1000 fold weaker (or more) than EGFR and other ErbB kinases. If so, might this 
nonetheless be relevant for receptor signaling? There are several reasons to suspect so. 
Activation of most RTKs involves initial ‗activating‘ trans-autophosphorylation 
events that follow ligand-induced dimerization (Schlessinger 2000), which typically 
increase the catalytic efficiency of the kinase by 150-1000 fold overall (Cobb, Sang et al. 
1989; Favelyukis, Till et al. 2001; Till, Becerra et al. 2002; Furdui, Lew et al. 2006). The 
resulting ‗full‘ kinase activation is required for the receptor to phosphorylate exogenous 
substrates such as insulin receptor substrate-1 (IRS-1) and phospholipase-C (PLC) 
(Furdui, Lew et al. 2006), but is clearly not necessary for the initial activating trans-
autophosphorylation steps (which are mediated by the much weaker unactivated kinase). 
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Indeed, literature estimates suggest that the initial trans-phosphorylation events 
responsible for activation of the insulin receptor and FGF receptor – mediated by a kinase 
domain that has not been autophosphorylated – involve kinases that are no more active 
than ErbB3 in our assays, which are strong arguments as to why the weak kinase activity 
of ErbB3 might be sufficient to promote (maybe transiently) receptor trans-
autophosphorylation within RTK dimers (such as ErbB2/ErbB3 heterodimers), which can 
be crucial for signaling in certain cellular contexts. 
The weak kinase activity of ErbB3 could be clinically relevant in cases where this 
receptor is implicated in mechanisms of resistance to agents that target other ErbB family 
members (Baselga and Swain 2009). ErbB3 signaling has been found to be important in 
resistance to gefitinib in NSCLC that arises from MET amplification (Engelman, 
Zejnullahu et al. 2007), and escape of ErbB2-overexpressing cell lines from growth 
inhibition or suppression by ErbB kinase inhibitors (Sergina, Rausch et al. 2007). Efforts 
to inhibit ErbB3 in these (and other) settings have focused on the use of therapeutic 
antibodies to date (Baselga and Swain 2009). However, if the kinase activity of ErbB3 
plays a role in the mechanism by which cancer cells bypass current ErbB-targeted cancer 
treatments, it will be an attractive target for clinical intervention. The development of 
small molecules that bind specifically to ErbB3‘s ATP-binding site would thereby 
provide useful therapeutic leads. Even if the kinase activity of ErbB3 is not signaling-
relevant, certain compounds of this class may be capable of stabilizing ErbB3 TKD 
conformations that do not support signaling (eg. mimic the effects of the V836R/L839Q 
double mutation described above), and therefore have therapeutic applications. 
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Further testing of the importance of ErbB3‘s weak kinase activity will require 
approaches that have not been described here. In the field of pseudokinases, the key 
question is that of whether the (pseudo) kinase domain communicates with other aspects 
of the signaling pathway using kinase activity per se or through protein-protein 
interactions that may be regulated by extracellular ligand binding. Distinguishing 
between these two possibilities is a difficult challenge. Using the mutation-based 
approach employed here, it is impossible to determine whether a kinase-inactivating 
mutation also alters the conformation. Thus, a mutation that aims to impair kinase 
activity might actually exert its negative effects on signaling by altering pseudokinase 
conformation.  To circumvent this problem, we have exerted significant effort in 
developing approaches to inhibit ErbB3‘s kinase activity pharmacologically.  We chose 
to use an approach employing analog-sensitive alleles that was pioneered by the 
laboratory of Kevan Shokat (Bishop, Kung et al. 1999; Alaimo, Shogren-Knaak et al. 
2001; Elphick, Lee et al. 2007). The basic idea is that one mutates the gatekeeper residue 
in the kinase of interest in order to render it sensitive to ‗bumped inhibitors‘ developed by 
the Shokat group.  If signaling is reconstituted using such an analog-sensitive allele 
(T768G in ErbB3), the available bumped inhibitors can be used as specific inhibitors to 
investigate the importance of its kinase activity.  Our experiences with this approach are 
summarized in Appendix 2, in order to document the technical problems experienced. In 
brief, we were able to apply the allele-sensitive analog approach in pilot studies with 
EGFR – as has also been achieved by Shokat and colleagues. However, signaling by the 
variant of ErbB3 expected to be analog sensitive (T768G) did not appear to be effectively 
inhibited by any available bumped inhibitors. (We were able to detect some effects of the 
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bumped inhibitors in cells, but the concentrations required to do so were sufficiently high 
that off-target effects are highly likely.) However, the lack of signaling response of 
analog sensitive ErbB3 to bumped inhibitors may be a consequence of the fact that 
ErbB3‘s kinase is relatively insensitive to broad-specificity kinase inhibitors (as 
mentioned in discussion of Figure 1.6), and therefore the affinities of the bumped 
inhibitors are not strong enough for ErbB3 kinase. In collaboration with the Shokat 
laboratory, we are now working to develop inhibitors that will specifically block the 
ErbB3 ATP-binding site with high affinity. These studies are still at an early stage, and 
further work to assess the role of ErbB3‘s kinase activity in cell signaling awaits progress 
with these compound development efforts. 
Although kinase-impaired ErbB3 mutants showed no apparent signaling defect in 
our cellular studies, our data do not necessarily rule out the possibility that ErbB3 can 
function as a kinase in cells. Indeed, the readout of our assay is limited to essentially a 
few specific tyrosine phosphorylation sites within the complex ErbB signaling network. 
A more general, proteomic approach such as SILAC might be required in order to study 
specific effects of disrupting ErbB3 kinase activity. Due to limited time and mass 
spectrometry resources, I have not been able to explore this approach. Another useful 
approach – for which my initial efforts are outlined in Appendix 2 – would be to use an 
analog-sensitive ErbB3 allele and bumped ATP in order to identify ErbB3 substrates as 
described by the Shokat group (Alaimo, Shogren-Knaak et al. 2001; Elphick, Lee et al. 
2007). Even at the absence of such data, we can formulate some reasonable hypotheses 
regarding ErbB3 kinase activation in cells: 
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1) ErbB3 might need other cellular factors to become fully activated in the cell, 
and this would not be captured in our simplified heterodimer system in BaF3/CHO cells 
or in our in vitro system. For example, a phenomenon of this sort might be relevant for 
MET/ErbB3 cross-talk, with MET signaling providing such activating factors. 
2) ErbB3 kinase may have a (uncharacterized) specific substrate preference, 
which is overlooked in my cellular studies. For example, it may be subject to a substrate-
assisted activation mechanism, which is not uncommon in other enzymes (Dall'Acqua 
and Carter 2000).  Such a mechanism could be particularly interesting in the case of 
ErbB3 kinase. Based on the structure, the only ―canonical‖ catalytic element missing in 
the ErbB3 kinase active site is a carboxylate group that is typically found on the 
conserved Asp (substituted by an Asn in ErbB3) proposed to function as a catalytic 
general base. A kinase substrate that provides such a carboxylate group at the right 
position might conceivably complement such a deficiency, and thus become an optimal 
substrate for ErbB3 kinase. 
Zhang et al. (Zhang, Gureasko et al. 2006) previously argued based on sequence 
comparisons that the ErbB3 TKD should be able to participate as an ‗activator‘ in 
allosteric activation of the EGFR kinase domain within the context of an asymmetric 
dimer, due to the similarity of its C-lobe to that of EGFR-TKD, but not as the ‗receiver‘ 
that becomes activated (because of substantial change in the ErbB3 N-lobe comparing to 
that of other ErbBs). Jura et al. (Jura, Shan et al. 2009) reported an ErbB3-TKD
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structure (PDB ID 3KEX) that is essentially identical to the structure described here, and 
have confirmed the ability of ErbB3-TKD to function as an allosteric activator of the 
59 
 
EGFR kinase domain in vitro. The structural differences in the N-lobe – including the 
shortened C helix described above – reinforce the argument that ErbB3-TKD cannot be 
activated by the same types of asymmetric dimer interactions thought to activate EGFR, 
ErbB4 and ErbB2 in heterodimeric complexes. If the ErbB3 TKD can function as a 
‗receiver‘ kinase in ErbB receptor dimers, it must do so though mechanisms that are quite 
different from those described for EGFR (Zhang, Gureasko et al. 2006) and ErbB4 (Qiu, 
Tarrant et al. 2008). 
A common argument for ErbB3 not being a physiologically relevant active kinase 
is that the N-lobe of ErbB3 TKD is different from that of other ErbBs, suggesting that it 
cannot function as a receiver kinase in the asymmetric dimer (and thus become activated). 
However, this argument implies that ErbB2 kinase is sufficiently active to carry out all 
the tyrosine phosphorylation of both C-tails in the heterodimer – of ErbB3 (in trans) and 
ErbB2 (in cis).  Given also that ErbB2 is an orphan receptor (and only forms 
heterodimers with other ErbBs), ErbB2 has no need to function as an activator kinase in 
the asymmetric dimer if it can mediate all phosphorylation by itself when activated by the 
other kinase in the heterodimer – which in turn suggests that the C-lobe interface of 
ErbB2 kinase does not have to be evolutionarily conserved. In fact, the ErbB2 C-lobe 
interface is highly conserved for asymmetric dimer formation, suggesting that, in the 
heterodimer with ErbB2, the other ErbB kinase also needs to be activated by ErbB2. 
Therefore, in the case of ErbB heterodimer involving ErbB3, ErbB3 kinase activity may 
be required for optimal signaling, although it may function through a different 
mechanism due to an altered N-lobe of ErbB3 TKD. 
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 So far we have been discussing the possibility that ErbB3 functions as a kinase in 
the cell. Our cellular studies have also shown that, even though kinase-inactivating 
mutations within ErbB3 TKD have no effect on its autophosphorylation or activation of 
Akt pathway, the V836R/L839Q double mutation compromises its ability to mediate 
neuregulin-induced Akt activation (but not levels of ligand-induced ErbB 
autophosphorylation). The finding that disrupting the hydrophobic patch between the 
activation loop helix and C helix within the ErbB3 kinase domain reduces downstream 
signaling activation provides supporting evidence for the hypothesis that ErbB3 TKD 
plays additional signaling roles beyond simply trans-activating neighboring ErbB kinases 
in ErbB3-containing heterodimers. Since the Akt pathway is directly involved in the 
development of cancers and their drug resistance via ErbB3 (Engelman, Janne et al. 2005; 
Sergina, Rausch et al. 2007; Castaneda, Cortes-Funes et al.), understanding how the 
ErbB3 kinase domain affects these signaling pathways should provide useful clues for 
developing therapeutic approaches in cancer. Unfortunately, my studies do not provide a 
clear view of the degree to which these changes affect ErbB3 kinase activity or ATP 
binding ability, since introducing these mutations – together or individually – into 
recombinant ErbB3 ICD protein (over-expressed in Sf9 insect cells) impairs protein 
stability, resulting in protein aggregation during protein purification and an inability to 
perform in vitro assays. Additional cellular studies are needed to uncover the molecular 
mechanism underlying ErbB3 TKD‘s regulation of downstream Akt signaling activation. 
Based on our CHO cell study it seems likely that ErbB3 kinase domain acts as a 
scaffolding protein that may allosterically regulate downstream signaling. Such function 
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is not usual, even for highly active kinases. For example, recent studies of Akt protein 
itself have revealed that, in addition to catalysis, its kinase domain can function as a 
protector for phosphorylated residues upon binding to ATP or ATP-competitive 
inhibitors (Chan, Zhang et al.; Lin, Lin et al.) – i.e. a scaffolding function. Binding of 
ATP (or inhibitor) stabilizes Akt kinase domain in a restricted conformation, which 
brings its phosphorylated T308 and S473 residues close to the kinase domain surface and 
shields them from phosphatases, whereas binding of ADP has the opposite effect 
(facilitating dephosphorylation) (Lin, Lin et al.). A similar function may exist in ErbB3 
kinase domain (the ‗inactive‘ conformation with ATP bound protects the phosphor-
tyrosine to be hydrolyzed), which could explain the observed cellular effect of 
V836R&L839Q double mutation. 
Several earlier studies have suggested a non-canonical role for the ErbB3 kinase 
domain, reminiscent of proposed ‗scaffold-like‘ functions for its pseudokinase domain: 
1) Using a yeast two-hybrid approach, Yoo et al. measured the interaction 
between ErbB3 ICD and the p85 unit of PI3K using a β-galactosidase reporter assay (Yoo 
and Hamburger 1998). Intriguingly, wildtype rat ErbB3 (which retains its catalytic base 
aspartate at D815 - unlike human ErbB3) generates low output signal, suggesting a lack 
of ErbB3 tyrosine phosphorylation. However, a D815N rat ErbB3 mutant facilitates the 
interaction and increase the assay output by 26 fold. Curiously, further mutating the 
conserved key lysine in the ATP binding site (i.e. rat ErbB3 K723A/D815N double 
mutant) abolishes this output increase. Although it is unclear whether the increase of 
signal is caused by ErbB3 kinase activity or change of conformation, this result implies a 
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functional role of Asn815 (instead of Asp) in ErbB3 TKD to modulate PI3K interaction – 
perhaps through a scaffolding function. 
2) In a study by Engelman et al. (Engelman, Janne et al. 2005), CHO cells 
transfected with wildtype EGFR showed sustained Akt activation even after 4 hours of 
EGF stimulation, whereas the long term phosphoAkt signal was abolished in CHO cells 
transfected with EGFR L858R (equivalent to ErbB3 V836R) activating mutant. This 
result is reminiscent of our CHO cell studies, in which the ErbB3 V836R/L839Q double 
mutant shows compromised ability to activate Akt pathway compared to wildtype ErbB3. 
In both cases, a specific conformation change accompanied with the mutations may 
disrupt the ability of ErbB protein (EGFR and ErbB3) to relay ligand stimulation to 
downstream signaling. 
In additional to the ErbB3 kinase described here, the signaling scaffold function 
has been proposed in many other pseudokinases, such as STRAD proteins to the kinase 
domain of LKB1, KSR for MAP kinase signaling, CASK in the synaptic protein complex, 
and the autonomous regulation of JAK2‘s pseudokinase domain to its upstream tyrosine 
kinase domain (summarized in (Boudeau, Miranda-Saavedra et al. 2006)). Intriguingly, 
all these pseudokinases have been reported to possess either ATP binding ability (for 
STRAD (Boudeau, Scott et al. 2004)) or kinase activity (for KSR1 (Hu, Yu et al. 2011; 
Shi and Lemmon 2011), CASK (Mukherjee, Sharma et al. 2008) and JAK2 
(Bandaranayake, Ungureanu et al. 2012)), although the exact roles of such functions are 
often unclear. Further in-depth analysis is required to provide us with a better picture of 
the role of pseudokinases such as ErbB3‘s.  
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1.6  Experimental Procedures for Chapter 1 
Materials and Reagents.  Mant-ATP (2'-(3')-O-(N-methylanthraniloyl)adenosine 
5'-triphosphate) was purchased from Invitrogen (Cat.# M-12417). 1, 2-dioleoyl-sn-
glycero-3-([N(5-amino-1-carboxypentyl)iminodi-acetic acid]succinyl} nickel salt 
(DOGS-NTA-Ni) was purchased from Avanti Polar Lipids. Primary antibodies 
mentioned here include: pY20 antibody (BIOMOL), anti-His5 antibody (QIAGEN), anti-
ErbB2 pTyr877, anti-ErbB3 pTyr1289, anti-Akt and anti-pAkt(Ser473) antibodies (Cell 
Signaling), anti-ErbB2 Ab8 and anti-ErbB3 Ab7 antibodies (NeoMarker/LabVision). 
Neuregulin 1β was purchased from R&D Systems Inc. 
Protein Expression and Purification. DNA fragments encoding the relevant 
regions of the human ErbB3 intracellular domain (ErbB3-ICD
665-1323
) or tyrosine kinase 
domain (ErbB3-TKD
665-1001
 and ErbB3-TKD
648-1001
) with an amino-terminal hexa-
histidine tag were subcloned into the pFastBac1 vector (Invitrogen) to generate 
corresponding baculoviruses using the Bac-to-Bac expression system (Invitrogen). 
Spodoptera frugiperda Sf9 cells were infected with the respective baculoviruses for 3 
days, and cells were collected and resuspended in buffer containing 20 mM HEPES pH 
8.0, 300 mM NaCl, 5% glycerol, 5 mM 2-mercaptoethanol and a protease inhibitor 
cocktail (Roche). ErbB3 proteins were affinity purified using Ni-NTA beads (Qiagen), 
followed by anion exchange chromatography with a UnoQ1 column (Bio-Rad) in 20 mM 
Tris pH8.0, 5% glycerol and 1 mM DTT (eluting with a linear gradient from 120 mM to 
1 M NaCl). ErbB3-containing fractions were concentrated and subjected to size exclusion 
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chromatography using a Superdex 200 column (GE Healthcare) equilibrated with 20 mM 
Tris pH 8.0, 200 mM NaCl, 5% glycerol and 1 mM DTT. 
Analysis of Autophosphorylation by Western Blotting. Vesicles containing 
DOGS-NTA-Ni at 5-10 % (mole/mole) in a background of dioleoylphosphatidylcholine 
(Sigma) were prepared as described (Zhang, Gureasko et al. 2006). Vesicles (50-150 M 
total lipid) were incubated with ErbB3 proteins at the concentrations noted in the legend 
to Figure 1.3 in 100 mM MOPS pH 7.4, containing 200 mM NaCl, 5 % glycerol, 1 mM 
ATP, 5 mM MgCl2, 2 mM MnCl2, and 0.1 mM DTT for 30 min at 25˚C, and the 
reactions were stopped by adding 50 mM EDTA and SDS-PAGE gel-loading buffer. 
Proteins were subjected to electrophoresis and transferred to nitrocellulose for Western 
blotting. Blots were probed with the indicated primary antibodies, and detection was 
accomplished using an HRP-conjugated anti-mouse (or rabbit) antibody (Amersham) and 
enhanced chemiluminescence. 
Mant-ATP Binding Assay. Binding assays were carried out in 20 mM Tris pH 
8.0, containing 200 mM NaCl, 5 % glycerol, 1 mM DTT, 5 mM MgCl2 and 0.6 μM 
Mant-ATP, with varying amount of ErbB3
648-1001
 protein. Fluorescence measurements 
were taken in triplicate using a Tecan SAFIRE II plate reader, with excitation wavelength 
of 280 nm and emission wavelength of 450 nm (5 nm bandwidth for both) to monitor 
FRET between protein and bound mant-ATP. 
Crystallization and Structure Determination. Purified ErbB3-TKD
665-1001
 was 
concentrated to 6 mg/ml and incubated with 5 mM MgCl2 and 1 mM AMP-PNP (Sigma). 
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Crystals were obtained using the hanging-drop method at 21°C by mixing the protein 
with an equal volume of reservoir solution (50 mM MOPS pH 7.4, 27 % (w/v) PEG8000, 
0.17 M (NH4)2SO4 and 15% glycerol). Needle-like crystals appeared within 2 days and 
were frozen in liquid nitrogen directly from the mother liquor. Diffraction data were 
collected at the Argonne Advanced Photon Source (beamline GM/CA CAT) and 
processed with the program HKL2000 (Otwinowski and Minor 1997). The structure was 
solved using molecular replacement (MR) using the program Phaser (CCP4 
(Collaborative Computational Project Number 4) 1994) with the inactive EGFR (V924R) 
TKD structure (PDB code 2GS7) (Zhang, Gureasko et al. 2006) as the search model. The 
program Coot (Emsley and Cowtan 2004) was used for model building, and refinement 
employed the programs REFMAC (CCP4 (Collaborative Computational Project Number 
4) 1994) and CNS (Brünger, Adams et al. 1998). TLS refinement (Winn, Isupov et al. 
2001) was employed in the later stages of refinement, using REFMAC (CCP4 
(Collaborative Computational Project Number 4) 1994), with anisotropic motion tensors 
refined for each lobe of the kinase domain. Structure figures were generated using PyMol 
(DeLano 2002).  
Cellular Studies. For studies with BaF3 cells, BaF3 cells were maintained in 
RPMI 1640 medium containing 10% FBS, 10mM HEPES, 2mM sodium pyruvate and 
1ng/ml IL3. To generate each stable BaF3 cell line co-expressing ErbB2 and ErbB3, a 
pIRES plasmid with the relevant full length ErbB3 at site A and full length ErbB2 at site 
B (after IRES) was introduced into BaF3 cells using electroporation with a BTX 600 
instrument. Briefly, 4x10
6
 cells were incubated with 40 µg DNA and electroporated at 
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1500 µF capacitance, 240 voltage and R10 resistance. 48 hours post-electroporation, 
G418 was added to a final concentration of 1mg/ml in the medium to select (over 10 days) 
for cells harboring the plasmid. Cells were then sorted for high ErbB2 expression using 
FACS and PE-labeled anti-HER2 antibody (Becton Dickinson). For autophosphorylation 
experiments, BaF3 cells were serum starved for 6 hours, then washed and resuspended in 
cold PBS at a density of 1x10
7
 cells/ml.  Cells were then stimulated with neuregulin1β 
(50ng/ml) for 10 min on ice. Cells were lysed in RIPA buffer (25 mM Tri-HCl pH 7.5, 
150 mM NaCl, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% SDS) containing 1 
mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM NaF, 5 mM Na2MoO4, and 0.2 
mM Na3VO4, and debris was pelleted by centrifugation. All glycoproteins in the lysate 
were then collected by incubating the lysate with concanavalin A beads (GE Healthcare, 
40ul beads for 10
7
 cells) for 2 hours at 4 ˚C.  Beads were then washed, resuspended in 
RIPA buffer (final volume of 100ul), and added 3x RSB with 5% BME and EDTA to a 
final concentration of 50mM. Samples were then boiled for Western blotting with 
indicated antibodies. 
For  Akt activation experiments, CHO cells were maintained in Hank‘s F12 media 
containing 10% FBS, 2 mM L-glutamine and 1.5 g/L sodium bicarbonate. For transient 
transfection, parental CHO cells were seeded at 4x10
5
 cells/well in 6-well plates. 24 
hours after seeding, cells were transfected with indicated pcDNA3.1-ErbB3 full-length or 
pRc/CMV-EGFR-ErbB3 chimera constructs using FuGENE transfection reagent (1.5 µg 
DNA and 6 µl reagent per well). 24 hours after transfection, medium was removed and 
replaced with serum-free medium overnight.  Cells were then stimulated with 
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neuregulin1β (or PBS as negative control) for 10-30 minutes, then lysed in RIPA buffer 
containing 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM NaF, 5 mM 
Na2MoO4, and 0.2 mM Na3VO4. Lysates were then subjected to Western blotting with 
indicated antibodies. For blots of total Akt, the corresponding pAkt(S473) blot was 
incubated with stripping buffer after HRP signal development to remove pAkt antibodies, 
and was then re-probed with anti-Akt antibodies.  
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Chapter 2 
Characterization of Derailed-Wnt Interactions 
  
69 
 
Ryk/Derailed family receptor tyrosine kinases (RTKs) are membrane signal transducers 
thought to mediate signaling induced by extracellular Wnt proteins. While developmental 
studies have characterized the indispensable roles of Ryk/Derailed family RTKs in cell 
patterning and differentiation, especially during neuronal development, few studies have 
attempted to uncover the molecular mechanisms of their signaling and ligand recognition. 
Utilizing biophysical methods, my study aims to understand the molecular interactions 
between Ryk/Derailed family RTKs and Wnt ligands, using Drosophila Derailed – 
DWnt5 as a model system. 
2.1 Overview of Ryk/Derailed – Wnt Signaling Pathway 
2.1.1 Introduction to Wnt proteins and Wnt Pathway 
Wnts, named after Wg (wingless) and Int (Integration 1), are a family of highly 
conserved, secreted proteins containing a characteristic Wnt domain that is comprised of 
~330 amino acids with a characteristic distribution of 24 cysteine residues. A total of 
nineteen Wnt family proteins have been identified in the deduced mammalian proteome. 
They play diverse roles in embryonic development and adult homeostasis, including 
segment polarity (Baker 1987) and neural tube development (Ikeya and Takada 1998) 
during embryogenesis and adult limb formation during metamorphosis (Yokoyama, 
Maruoka et al.). Wnt proteins are typically lipid modified, rendering the proteins 
hydrophobic (Willert, Brown et al. 2003; Takada, Satomi et al. 2006; Kurayoshi, 
Yamamoto et al. 2007).  
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In canonical Wnt signaling, the Wnt – β-catenin – TCF axis plays a central role. 
In the absence of Wnt signaling, β-catenin is constantly phosphorylated in a protein 
complex formed by Axin/APC/casein kinase 1 (CK1)/glycogen synthase kinase 3 
(GSK3). Phosphorylated β-catenin is then ubiquitinated and degraded by proteasome. 
The binding of Wnt proteins to the cysteine-rich domain (CRD) of Frizzled receptors 
(their best known cell surface receptors) and LRP 5/6 co-receptors leads to recruitment of 
Dishevelled (Dvl) protein through its PDZ domain to the intracellular tail of the Frizzled 
receptor and subsequent phosphorylation of LRP6. Phosphorylated LRP protein on the 
membrane then recruits the Axin complex, thus freeing β-catenin protein from 
degradation in the cytosol. Accumulated β-catenin then translocates into the nucleus and 
binds to DNA-bound TCF transcription factors, which in turn initiates transcription of 
genes that are controlled by TCF promoter (Figure 1A, left) (Logan and Nusse 2004; 
MacDonald, Tamai et al. 2009; Clevers and Nusse 2012). 
Very recently, a crystal structure of Xenopus Wnt8 (XWnt8) in complex with the 
CRD of mouse Frizzled-8 (mFz-8) was reported (Figure 2.1B) (Janda, Waghray et al.). 
The CRD of mouse Frizzled-8 displays a mostly α-helical structure as described before 
(Dann, Hsieh et al. 2001).  XWnt8 comprises a large N-terminal region that is mostly α-
helical (with four short β strands formed as a sheet on one side) and a smaller C-terminal 
region that contains two long β strands in a hairpin-like configuration. The crystal 
structure also revealed Ser207 of XWnt8 (equivalent to Ser868 of DWnt5) as a lipidation 
site. XWnt8 binds to mFz-8 CRD through two separate loop regions. The first binding 
region, located on the N-terminal side of XWnt8, mainly uses the palmitoyl lipid moiety 
71 
 
(PAM in Figure 2.1B) to engage a hydrophobic groove on the CRD. The second binding 
region, which is located in between the two long β strands on the C-terminal side of 
XWnt8, consists of a long loop and is thought to contribute to selectivity of Wnt binding 
to CRDs from different Frizzled receptors. However, it is yet unclear from this structure 
how binding of Wnt ligand leads to signaling through Frizzled receptors. 
In addition to the canonical Wnt signaling, Wnt proteins also participate in the 
orientation of planar cell polarity (PCP) through signaling to c-Jun N-terminal kinase 
(JNK) (Wang 2009), and control of cell migration through the activation of 
heterotrimeric G proteins that leads to increased level of intracellular Ca
2+
 and signaling 
by calcium dependent kinases (De 2011) (Figure 1A, right). 
Increasing evidence has shown unequivocally that the canonical, PCP, and 
Wnt/Ca
2+
 pathways are only some of the many signaling events initiated by Wnt binding, 
and the specific cellular response for any Wnt ligand reflects the combined actions of a 
diverse set of Wnt receptors present on the cell surface (van Amerongen, Mikels et al. 
2008). In addition to the ten Frizzled receptors in mammals, the RTKs Ryk and Rors 
have been shown to act as Wnt receptors on the cell surface that mediate Wnt signaling 
(Figure 1A). Ror1 and Ror2 contain CRD domains that are related to those in Frizzleds. 
On the other hand, Ryk/Drl lack a CRD-related domain for Wnt binding. Instead, they are 
thought to bind Wnts through their extracellular WIF domains, which are homologous to 
human Wnt Inhibitory Factor-1 (hWIF-1) protein. 
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Figure 2.1: Overview of Wnt signaling. (A) Illustration of canonical and non-canonical Wnt signaling 
(adapted from (Katoh and Katoh 2007)). (B) Crystal structure of Xenopus Wnt8 (XWnt8) in complex with 
the cysteine rich domain (CRD) of mouse Frizzled-8 (mFz-8) (PDB: 4F0A) (Janda, Waghray et al. 2012). 
The lipid moiety of XWnt8 is labeled PAM. 
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2.1.2 Introduction to Ryk/Derailed Family Receptor Tyrosine Kinases 
Ryk (Related to tYrosine Kinases) is a protein with a single transmembrane domain that 
belongs to the vertebrate RTK family, first isolated in the early 1990s using PCR with 
degenerate primers (Hovens, Stacker et al. 1992; Yee, Bishop et al. 1993). Ryk orthologs 
are also present in invertebrate, such as Derailed in Drosophila melanogaster and LIN-18 
in C. elegans.  Ryk and its invertebrate orthologs are characterized by an extracellular 
WIF (Wnt Inhibitory Factor) domain (see below) and an intracellular pseudokinase 
domain (Figure 2.2).  
Ryk is expressed in various mammalian tissues during both embryogenesis and 
adulthood (Halford, Oates et al. 1999). Homozygous Ryk-null mice display distinctive 
development defects, including a shortened craniofacial region and diminished limbs 
(Halford, Armes et al. 2000). These morphological features are similar to the symptoms 
observed in mice lacking members of the EphB family of RTKs (Bush and Soriano 2010), 
implying signaling crosstalk or collaboration between the Ryk and EphB classes of RTKs. 
Accordingly, Ryk has been shown to co-immunoprecipitate with both EphB2 and EphB3 
(Halford, Armes et al. 2000; Trivier and Ganesan 2002; Kamitori, Tanaka et al. 2005). In 
addition, overexpression of Ryk has been reported to cause transformation of NIH3T3 
cells, leading to their tumorigenicity when injected into nude mice (Katso, Manek et al. 
1999). 
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Figure 2.2: Domain organization of Ryk and Derailed (mature protein with signal peptide cleaved). WIF: 
Wnt Inhibitory Factor domain; S/T Rich: Serine/Threonine rich segment; PTK: Protein Tyrosine Kinase 
domain. 
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The best characterized Ryk ortholog in invertebrate is Derailed (Drl) in D. 
melanogaster. Drl protein has the same domain organization as human Ryk (Figure 2.2), 
with 34% sequence identity between their WIF domains and 48% sequence identity 
between their pseudokinase domains. Drl was first isolated based upon its function in 
neuronal axon pathfinding (Callahan, Muralidhar et al. 1995). Abnormal muscle 
attachment to epidermis was also observed in drl knockout flies (Callahan, Bonkovsky et 
al. 1996). At the same time, another research group independently identified Drl as the 
gene responsible for the learning and memory deficits displayed in fly linotte mutants 
(Dura, Taillebourg et al. 1995).  
Signaling by receptor tyrosine kinases is known to be initiated through their 
stimulation by extracellular ligands (Lemmon and Schlessinger 2010). Ryk and Derailed 
are no exceptions to this rule. Owing to the presence of a WIF-homolgous domain in their 
extracellular regions, Ryk and Derailed have been characterized as potential receptors for 
Wnt ligands (to which human WIF-1 protein is known to bind), and a variety of studies 
have shown that they contribute to the complex regulation of tissue development by Wnt 
signaling. 
2.1.3 Introduction to Human Wnt Inhibitory Factor-1 (hWIF-1) 
Human WIF-1 is a secreted protein known to bind various Wnt proteins, and is thought to 
inhibit their signaling by preventing Wnts from binding to their cell-surface receptors. 
hWIF-1 is composed of an N-terminal signal sequence and a WIF domain followed by 
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five EGF repeats and a short C-tail. When overexpressed in Xenopus laevis embryos, 
hWIF-1 causes their dorsalization or anteriorization, mimicking phenotypes observed 
when Xenopus Wnt8 (XWnt8) signaling is blocked (Hsieh, Kodjabachian et al. 1999).  
hWIF-1 was also found to block the ability of overexpressed XWnt8 to induce axis 
induction in a dose-dependent manner, and the WIF domain alone is as effective in 
inhibiting this process as full-length hWIF-1 (Hsieh, Kodjabachian et al. 1999). A total of 
six mammalian Wnt proteins have been reported to associate with hWIF-1 (Malinauskas, 
Aricescu et al. 2011). In vitro binding studies have been carried out to map the regions of 
WIF-1 responsible for Wnt binding (Malinauskas, Aricescu et al. 2011). Full-length WIF-
1 binds tightly to Wnt3a with KD of 60 nM. Both WIF domain and EGF repeats appear to 
contribute to Wnt-association: the WIF domain alone binds Wnt3a with a KD of 3.4 M, 
whereas a fragment containing the EGF repeats alone binds Wnt3a with a KD of 0.9 M 
(Malinauskas, Aricescu et al. 2011).  
NMR and X-ray crystallographic studies have provided structural insights into the 
WIF domain (Liepinsh, Banyai et al. 2006; Malinauskas, Aricescu et al. 2011): the WIF 
domain adopts an overall immunoglobulin-like fold, with nine beta strands and two short 
alpha helices (Figure 2.3 A&B). Interestingly, both studies have reported WIF binding to 
hydrophobic detergent or lipid.  The NMR-based study reported tight binding of the 
detergent Brij-35 between the second beta-strand and second alpha helix of the WIF 
domain (Liepinsh, Banyai et al. 2006; Malinauskas, Aricescu et al.). In the crystal 
structure, the alkyl-chains of a phospholipid were found to penetrate into the core of WIF 
domain from the opening between the two alpha helices (Malinauskas, Aricescu et al. 
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2011). Given the fact that Wnts are typically lipid-modified, these observations raised the 
intriguing possibility that the WIF domain binds to Wnts by recognizing their lipid 
moiety as well as regions of the Wnt protein itself. However, the region(s) on the WIF 
domain that are directly responsible for Wnt binding have not yet been identified 
experimentally. 
 
 
Figure 2.3: Reported structures of human Wnt Inhibitory Factor -1 (hWIF-1). (A) NMR structure of WIF 
domain of hWIF-1 with no lipid (PDB: 2D3J) (Liepinsh et al. JMB 2006). (B) Crystal structure of WIF 
domain of hWIF-1 with DOPC bound (PDB: 2YGN) (Malinauskas, Aricescu et al. 2011). 
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2.1.4 Ryk/Drl Interact with Wnts and Mediate Wnt Signaling 
The WIF domain of human Ryk contains about 130 amino acids and shares 23% 
sequence identity to hWIF-1 (Figure 2.4A). Lu et al. (Lu, Yamamoto et al. 2004) have 
demonstrated that the Ryk WIF domain co-immunoprecipitates with Wnts (Wnt-1 or 
Wnt-3a), and that overexpression of Ryk increases Wnt-induced TCF-driven transcription 
in 293T cells. Conversely, RNAi knockdown of Ryk expression abolishes TCF pathway 
activation by Wnts. Ryk siRNA also causes a reduced level of Wnt3a-induced neurite 
outgrowth in dorsal root ganglion (DRG) explants (Lu, Yamamoto et al. 2004). Later 
studies of Ryk-Wnt signaling have focused mainly on its effects in neuronal development. 
Schmitt et al. examined the effect of Ryk-mediate Wnt3 signaling on retinal ganglion 
cells (RGCs) of chick (Schmitt, Shi et al. 2006), and showed that Ryk mediates a Wnt3-
induced axonal repulsion (inhibitory) response in neuron explants, which could be 
inhibited by a specific anti-Ryk serum.  By contrast, Frizzleds mediate an axonal 
attraction response – which is thought to collaborate with repulsive Ryk signaling in 
retinotectal topographic mapping (Schmitt, Shi et al. 2006). Similar Wnt-repulsive effects 
of Ryk have also been reported by other studies in Ryk knockout mice (Keeble, Halford 
et al. 2006) and in cultured neurons treated with anti-Ryk antibodies (Liu, Shi et al. 2005). 
Since Wnts are typically distributed in a local concentration gradient in developing 
organisms, the differential responses of Ryk-expressing and Frizzled-expressing neurons 
presumably contribute to the formation of intricate neuron topographic patterning. 
Recently, Ryk has also been implicated in cell fate determination of neural progenitor 
cells (NPCs); knocking out Ryk from NPCs switches neural differentiation towards 
79 
 
oligodendrocyte neurons, whereas re-introducing Ryk reverses this preference and 
instead promotes differentiation towards GABAergic neuron (Li, Hutchins et al. 2009). 
 
Figure 2.4: Sequence alignments of WIF domains. (A) Alignment of WIF domains in Drosophila Derailed, 
human Ryk and human Wnt Inhibitory Factor -1. (B) Alignment of WIF domains in Drosophila Derailed, 
Drosophila Doughnut, Drosophila Derailed-2 and human Ryk. Alignments are generated using ClustalW 
and colored using JalView (Clustalx color scheme). 
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The Drosophila melanogaster Ryk ortholog, Drl, has been shown to mediate 
signaling by Drosophila Wnt5 (DWnt5), an ortholog of human Wnt5s (hWnt5). 
Extensive studies have characterized Drl-DWnt5 mediated axon pathfinding in the 
Drosophila embryonic central nervous system (CNS). In the Drosophila ventral nerve 
cord, many neurons need to project axons across the midline to the opposite side of the 
CNS via either the anterior commissure (AC) or posterior commissure (PC). Autonomous 
expression of the Drl receptor guides a subset of axons to project through the anterior 
commissure (rather than the posterior commissure) of each segment, and embryonic 
neurons in flies lacking Drl showed defects in choosing the correct crossing path (hence 
the name of the gene: derailed) (Callahan, Muralidhar et al. 1995; Bonkowsky, 
Yoshikawa et al. 1999). Drl guides commissure choice through its interaction with 
DWnt5, which is expressed predominantly on posterior commissural neurons and induces 
repulsive signals in the Drl-expressing subset of neurons to promote their projection into 
the anterior commissure (Fradkin, van Schie et al. 2004). Abolishing DWnt5 expression 
undermines this guidance function of Drl, and causes a lack of separation between AC 
and PC neurons when crossing the midline (Yoshikawa, McKinnon et al. 2003; Fradkin, 
van Schie et al. 2004). Yoshikawa et al. also showed that a Drl ectodomain-Fc fusion 
protein is able to accurately label the DWnt5 expression region in Drosophila embryos  as 
well as immunoprecipitate DWnt5, suggesting physical interaction between DWnt5 and 
Drl (Yoshikawa, McKinnon et al. 2003). Drl-mediated DWnt5 signaling has also been 
implicated in the patterning of olfactory receptor neurons (ORNs) in the Drosophila 
antennal lobe (Yao, Wu et al. 2007; Sakurai, Aoki et al. 2009), in the development of  
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mushroom bodies (Moreau-Fauvarque, Taillebourg et al. 1998; Grillenzoni, Flandre et al. 
2007), and in salivary gland migration (Harris and Beckendorf 2007). 
In addition to Drl, two other Ryk homologs, Derailed-2 (Drl-2) and Doughnut 
(Dnt), are also found in Drosophila (Figure 2.4B). The Drl and Drl-2 WIF domains share 
44% sequence identity. Drl-2 was shown to be predominantly expressed in ORN axons 
and to participate in development of the olfactory system – with functional 
complementarity to Drl-DWnt5 signaling (Sakurai, Aoki et al. 2009).  The Drl and Dnt 
WIF domains share 64% sequence identity.  Although Dnt has a distinct expression 
pattern from that of Drl during embryogenesis, targeted overexpression of Dnt can 
partially rescue embryonic muscle attachment defects in Drl null mutants. (Oates, 
Bonkovsky et al. 1998) 
2.1.5 The Pseudokinase Domains of Ryk/Drl Lack Kinase Activity but are Capable 
of Signal Transduction 
The signaling cascades triggered after Wnt binding to Ryk/Drl – which mediate the 
repulsive signals outlined above – are unclear. The typical RTK activation scheme – 
where ligand-induced receptor dimerization induces kinase activation and 
autophosphorylation – is unlikely in this case. Despite having a highly conserved 
intracellular kinase domain, Ryk/Drl are considered to have kinase-inactive 
‗pseudokinase‘ domains, due to sequence alterations at several conserved residues that 
are important for the activity of ‗canonical‘ kinases (summarized in (Halford and Stacker 
2001)). Specifically,  
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1. The first glycine in the GxGxxG ‗P-loop‘ motif is altered (mostly replaced by 
glutamine). 
2. The DFG motif, thought to be a nexus of kinase regulation, is replaced by the 
sequences DNA (in Ryk) or DSA (in Drl). 
3. In the ATP binding pocket, a conserved alanine is replaced by a bulky 
phenylalanine (in Ryk) or leucine (in Drl) in the VAIK motif, which may prevent 
the accommodation of ATP substrate. 
Several studies have attempted to address the question of whether Ryk/Drl can 
function as kinases, and if not, how they might mediate signal transduction. Yoshikawa et 
al. showed that a Drl mutant with the ―invariant‖ lysine in its kinase domain substituted 
by alanine (K371A) – a mutation that greatly impairs activity of most kinases – is 
indistinguishable from wildtype Drl in phenotypic rescue or gain-of-function assays 
studying fly axon guidance and muscle attachment, suggesting that kinase activity is not 
required for Drl-mediated signaling (Yoshikawa, Bonkowsky et al. 2001). In another 
study (Taillebourg, Moreau-Fauvarque et al. 2005), the same presumed Drl kinase-dead 
mutant was also shown to phenocopy wildtype Drl in inducing a gain-of-function 
phenotype involving mushroom body defects in flies, despite a lower level of mRNA 
expression. Similar to Drl, no kinase activity has been observed for Ryk kinase domain 
(Trivier and Ganesan 2002). A TrkA extracellular – Ryk intracellular chimeric protein 
also displayed lack of autophosphorylation upon NGF stimulation (Katso, Russell et al. 
1999).  
83 
 
In summary, so far no role in phosphotransfer catalysis has been observed for the 
kinase domain of Ryk/Drl family RTKs. Yet the highly conserved cytoplasmic region 
seems to be capable of signaling (Yoshikawa, Bonkowsky et al. 2001). In neuronal cells, 
the Ryk intracellular domain (ICD) is thought to possess a Notch receptor like function. 
After stimulation by Wnt binding, the Ryk ICD is cleaved off and translocates into the 
nucleus, where it functions to promote neuronal differentiation (Lyu, Yamamoto et al. 
2008; Lyu, Wesselschmidt et al. 2009). Indeed, Ryk ICD fused to a nuclear localization 
signal (NLS) can functionally replace full-length Ryk in cell fate determination of neural 
progenitor cells (Zhong, Kim et al. 2011). In studies with TrkA ECD/Ryk ICD chimeras, 
the chimeric protein with the wildtype Ryk kinase domain is able to induce Erk 
phosphorylation and activate MAPK pathway. Interestingly, mutating the invariant lysine 
K334 to alanine in this case abolishes Erk phosphorylation (Katso, Russell et al. 1999). 
Wouda et al. also showed that Src family kinases bind to and phosphorylate Drl, and 
participate its downstream signaling (Wouda, Bansraj et al. 2008). Although these studies 
have demonstrated a clear signaling capability of Ryk ICD, the mechanism of signal 
transduction from Wnt binding to intracellular signaling activation remains unclear. 
2.1.6 Biophysical Characterization of Drl-DWnt5 Interactions as a Model System 
for Ryk/Drl Signaling 
As summarized above, extensive studies have documented important roles of Ryk/Drl 
RTKs in Wnt signaling and embryonic development, especially in axon pathfinding. In 
sharp contrast, little is known regarding the molecular mechanisms of Wnt-Ryk/Drl 
interactions or the resulting cellular signal transduction. Even the very first step of this 
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signaling pathway – binding of Wnts to the WIF domain of Ryk/Drl – is poorly 
understood, and many questions remain regarding this process. For example, current 
evidence for binding of Wnts to Ryk/Drl is based mainly on co-immunoprecipitation or 
the use of anti-Ryk/Drl postimmune sera. These studies do not preclude the possibility 
that, rather than interacting directly with Wnt proteins, Ryk/Drl communicate indirectly 
with Wnts through an intermediate factor. Even if the binding is direct, other proteins 
may be necessary to form a functional signaling unit. Indeed, Ryk can be co-
immunoprecipitated with both Wnt and Frizzled (Lu, Yamamoto et al. 2004), and sFRP2 
(Secreted Frizzled-related Protein 2) blocks only Wnt3-Frizzled5 interactions but not 
Wnt3-Ryk interactions (Schmitt, Shi et al. 2006), suggesting the possibility of a Ryk-
Wnt-Frizzled ternary complex. 
To begin addressing these questions, it is essential first to characterize the 
interaction between Ryk/Drl and Wnt at a molecular level using tools from biophysical 
and structural biology. In my efforts to understand the mammalian Ryk-Wnt system, I 
encountered major experimental difficulties with obtaining well-behaved recombinant 
Ryk and Wnt proteins. On the other hand, the Drosophila system has proven far more 
tractable, since both Drl and DWnt5 could be readily obtained using insect cell 
expression systems. Owing to the high sequence homology and functional similarity 
between Drl and Ryk, understanding Drl-DWnt5 signaling should also shed light on the 
molecular mechanism of their mammalian counterparts.  
Using Drl-DWnt5 as a model system, my goals were to address the following 
questions: 
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1. Does Ryk/Drl interact directly with Wnt proteins? If so, what is the binding affinity? 
2. Which protein region(s) is(are) responsible for the formation of Ryk/Drl-Wnt 
complexes?  Does the region of Wnt that binds Ryk/Drl overlap with the region that 
binds Frizzleds – so that binding to the two classes of receptor would be mutually 
exclusive – or do different regions of the Wnt surface bind to the different receptors? 
In describing my studies, I start by describing the expression and purification of 
individual proteins, followed by characterization of their binding using ‗pull-down‘ and 
surface plasmon resonance (SPR) studies. I will then discuss structural insights into the 
properties of the WIF domain from a Drl homolog that I have obtained using X-ray 
crystallography. Based on this structure, I have generated and characterized a set of 
mutations in the Drl WIF domain in order to locate the primary site for DWnt5 binding. 
My studies serve as a good starting point for understand recognition of Wnt proteins by 
the Ryk/Drl extracellular regions, and for interrogating Ryk/Drl signaling at a molecular 
level. 
2.2 Biophysical Characterization of Derailed-DWnt5 Interactions 
2.2.1 Expression, Purification and Characterization of Drosophila Derailed and 
DWnt5 Proteins 
I was able to express the Drl extracellular region (residues 1 - 242) with a C-terminally 
appended 6xHis tag in Sf9 cells at high levels.  Purification of the secreted protein was 
achieved as described in Experimental Procedures. Pure, glycosylated Drl full 
extracellular region (sDrl) runs as a 35 kDa protein on SDS-PAGE gels (Figure 2.5A). 
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Protein constructs with serial truncation from the C-terminus (up to residue 180) could be 
expressed with similar yields and purified in the same way. Three N-linked glycosylation 
sites (N63, N99 and N143) were identified within the Drl WIF domain. Mutating each of 
these Asn residues independently to Gln causes disappearance of the upper (slower 
mobility) band of sDrl in SDS-PAGE (Figure 2.5B), suggesting the presence of sugar 
moieties at all three N-glycosylation sites. 
 
 
Figure 2.5: Characterization of recombinant Derailed extracellular region. (A) SDS-PAGE of purified, 
wildtype Drl full extracellular region (sDrl) with a C-terminally appended 6xHis tag. This gel was stained 
with Coomassie Blue.  (B) Western blot showing that point mutations at any of the predicted N-linked 
glycosylation sites in the Drl extracellular region (N63, N99, or N143) resulted in faster protein migration 
during SDS-PAGE, suggesting removal of glycan. sDrl proteins were detected using a pentahistidine 
antibody that recognizes the 6xHis tag. 
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DWnt5 contains an unusually long (~500 amino acids), non-conserved N-terminal 
region (yellow in Figure 2.6A) as well as a ~150aa insert in the Wnt domain (blue in 
Figure 2.6A) when compared with other Wnt proteins that consist primarily only of the 
Wnt-homologous region (green in Figure 2.6A). In a Drosophila imaginal disc cell line, 
DWnt5 protein is secreted in two forms – a full length, 140 kDa glycoprotein and a 
proteolytic 80 kDa fragment (Fradkin, Noordermeer et al. 1995). 
When full length DWnt5 is expressed in Drosophila Schneider 2 (S2) cells, it is 
secreted mainly as a ~70 kDa glycoprotein (Figure 2.6B), similar in size to the reported 
80 kDa proteolytic DWnt5 fragment (Fradkin, Noordermeer et al. 1995). The identity of 
the DWnt5 protein was confirmed by Western blotting using two polyclonal antibodies 
(kindly provided by Dr. Lee Fradkin (Fradkin, Noordermeer et al. 1995)). The epitope for 
antibody A is located just N-terminal of the Wnt domain, whereas the epitope for 
antibody B is located within the Wnt domain insert (Figure 2.6A). 
Secreted, mature DWnt5 protein was extracted from the medium and purified as 
described in the Experimental Procedures (Figure 2.6C).  Surprisingly, the DWnt5 
protein is stable in solution without detergents, a property that contrasts with that 
described for other known Wnt proteins. The mature, ~70 kDa DWnt5 protein is the 
result of proteolytic cleavage close to the C-terminus of the N-terminal region, as 
suggested by the fact that it is recognized by antibody A (Figure 2.6B). N-terminal 
protein sequencing at the Keck Facility (Yale University) showed that the major N-
terminal starting sequence of mature DWnt5 protein is SQPSIS (residue 455 - 460). ESI 
mass spectrometry of the purified protein (conducted by the CHOP Proteomics Core) also 
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showed an absence of peptide coverage at N-terminal domain. Taken together, the mass 
spectrometry and Western blotting results suggest that purified, mature DWnt5 protein 
consists primarily of the Wnt domain, extending from residue 455 of DWnt5 to residue 
1004 (although the C-terminus has not been confirmed). 
To identify N-glycosylation sites within the mature DWnt5 protein, purified 
DWnt5 protein was treated with PNGaseF in H2O
18
 and subjected to ESI mass 
spectrometry (conducted by the CHOP Proteomics Core). Three N-glycosylation sites 
were identified: N484-485 (KVSMENNTSVTD), N724 (NVDAKNDTSLV) and N952 
(RVCHKNSSGLE). Indeed, PNGaseF-treated DWnt5 showed increased mobility in SDS-
PAGE, confirming the presence of surface-accessible N-linked glycosylation (Figure 
2.6D). Surprisingly, mass spectrometry data readily identified peptide fragments 
containing unmodified S868, the putative lipid modification site of DWnt5. This is an 
unexpected result, which suggests that our recombinant DWnt5 protein is not lipid 
modified at this site. The lack of lipid modification is consistent with the fact that our 
DWnt5 protein has much better solubility characteristics than those seen for other Wnts.  
The fact that we can generate quantities of purified DWnt5 useful for biochemical and 
biophysical studies may open up unique opportunities for quantitative study of Wnt 
signaling. 
In order to examine whether the unique Wnt domain insert of DWnt5 (residue 681 
to 838) is involved in Drl binding, a construct was generated in which the insert region of 
DWnt5 was replaced with a short sequence (RERSFKRGSREQG) found in the equivalent 
region of Wnt5 from the jumping ant Harpegnathos saltator, which has no such insert. 
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The new, shortened construct is named DWnt5ΔB due to its lack of epitope for antibody 
B. The mature form of purified DWnt5ΔB migrates more slowly in SDS-PAGE 
compared to wildtype DWnt5 (Figure 2.6B left blot), possibly due to an alternative N-
terminal cleavage site being used – or a different glycosylation pattern. Western blotting 
of DWnt5ΔB confirmed the identity of the protein construct; it can be detected readily 
using antibody against epitope A, but not with antibody against epitope B (Figure 2.6B 
right blot), since this epitope has been removed. 
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Figure 2.6: Characterization of DWnt5 protein. (A) Domain organization of DWnt5. Starting from the N-
terminus: signal-peptide sequence (ss), N-terminal region (yellow), Wnt-homologous domain (green) and 
Wnt domain insert (blue). The locations of two epitopes for DWnt5-specific rabbit polyclonal antibodies 
are labeled A and B.  (B) Western blots showing DWnt5 proteins secreted from S2 cells. DWnt5 was 
detected by two different DWnt5 antibodies as indicated in (A). (C) SDS-PAGE gel of purified, mature 
DWnt5 wildtype protein. (D) PNGaseF treatment of DWnt5 protein leads to increased mobility in SDS-
PAGE. 
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2.2.2 Analysis of Derailed-DWnt5 Interactions by in vitro Pull-down and SPR 
For an initial view of Derailed-DWnt5 interactions, we used a simple pull-down assay to 
ask if the two recombinant proteins interact. Two C-terminally 6xHis tagged constructs 
of purified recombinant Drl extracellular region (Drl residues 1-207 and Drl residues 1-
219) were used. Each sDrl protein was mixed with conditioned S2 medium containing 
secreted DWnt5 protein. NiNTA beads were then added to the protein mixture to extract 
sDrl proteins from the solution. The ability of sDrl proteins to pull down DWnt5 protein 
from the medium was then examined by Western blotting with DWnt5 specific antibodies. 
As shown in Figure 2.7, both sDrl proteins were able to extract DWnt5 from the solution, 
as evidenced both by the loss of DWnt5 in the supernatant fraction and enrichment of 
DWnt5 in the pull-down fraction. On the contrary, NiNTA beads did not effectively pull 
down DWnt5 when the 6xHis-tagged sDrl protein was not included in the assay. These 
results suggest that purified recombinant sDrl proteins interact with DWnt5 in vitro. 
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Figure 2.7: Drl ectodomains are capable of pulling down DWnt5 from conditioned medium. S2 media 
containing secreted DWnt5 protein (pre-concentrated by 10 fold) was mixed with NiNTA beads in the 
presence (or absence) of purified Drl extracellular domains with an appended 6xHis tag. Two sDrl 
constructs were used. One encompasses Drl residues 1-207 and the other encompasses Drl residues 1-219. 
As controls, DWnt5-containing medium or the individual sDrl proteins were also mixed with NiNTA beads 
on their own. Both sDrl proteins bound strongly to NiNTA beads whether DWnt5 was also present or not.  
By contrast, DWnt5 was only enriched in the NiNTA pull-down fraction when added together with one of 
the His-tagged sDrl proteins. NiNTA pull-down fractions were resuspend in 20% of the original media 
volume, hence the stronger DWnt5 band intensity in the sDrl-free pull-down fraction compared to loading 
control. A sample of S2 medium before pull-down experiment was analyzed as loading control. 
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For more quantitative studies of direct interaction between purified sDrl and 
DWnt5 proteins, we used surface plasmon resonance (SPR) with a Biacore 3000 
instrument. Purified DWnt5 was immobilized onto a CM5 sensor chip using amine 
coupling. Serial dilutions of sDrl proteins were then injected, and steady state binding to 
the DWnt5-derivatized surface was recorded in SPR response units (RUs), corrected for 
refractive index effects using a mock-derivatized control sensorchip surface. Steady state 
RU values measured at different sDrl concentrations were then fit to a single-binding-site 
hyperbolic curve (Figure 2.8A & B and Table 2.1). Wildtype, full sDrl (1-242) binds 
directly to DWnt5 with a dissociation constant (KD) of 0.63 µM. Elimination of the C-
terminal region of sDrl does not significantly affect the binding affinity; sDrl (1-180) 
bound DWnt5 with a KD of 0.36 µM, suggesting that DWnt5 binding is mediated mostly 
by the WIF domain, which ends at amino acid 161. The presence of sugar moieties at 
N63 and N143 of sDrl also appears to have minimal influence on DWnt5 binding; sDrl 1-
180 with both of these glycosylation sites mutated to glutamine (N63Q/N143Q) also 
bound DWnt5 with a very similar KD (0.54 µM). 
To investigate whether the long insert region of DWnt5 contributes to Drl binding, 
purified DWnt5ΔB protein was immobilized onto a CM5 sensorchip in the same way as 
described for wildtype DWnt5, and its binding affinity for sDrl(1-242) was measured by 
SPR (Figure 2.8C). The results show that DWnt5 wildtype and DWnt5ΔB proteins have 
almost identical binding affinities for sDrl (Table 2.1).  It is therefore clear that Drl 
binding does not require the unique insert region of DWnt5. 
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Figure 2.8: SPR studies of sDrl proteins binding to DWnt5 variants. (A) SPR studies with a series of 
injections of the noted sDrl proteins onto a CM5 chip with immobilized wildtype DWnt5 protein. (B) A 
representative SPR sensorgram of immobilized DWnt5 binding to sDrl(1-242) (at 320 nM concentration). 
Colored squares represent actual data points. Sensorgram for DWnt5 immobilized CM5 chip surface is 
colored red, and sensorgram for mock-derivatized control sensorchip surface is colored blue. Injection of 
sDrl(1-242) protein solution starts at ~190 s and ends at ~430 s. (C) SPR studies in which a series of 
injections of sDrl(1-242) at the indicated concentrations were applied to sensorchip surfaces containing 
immobilized wildtype DWnt5 or DWnt5ΔB. 
 
 
Table 2.1: SPR studies of different sDrl variants binding to DWnt5. Upper: sDrl constructs binding to 
immobilized wildtype DWnt5. Lower: sDrl 1-242 binding to immobilized DWnt5ΔB. 
Analyte Binding KD  (µM) to immobilized wildtype DWnt5 
sDrl 1-242 0.63 ± 0.08 
sDrl 1-183 0.36 ± 0.08 
sDrl 1-180 N63Q&N143Q 0.54 ± 0.05 
 
Analyte Binding KD  (µM) to immobilized DWnt5ΔB 
sDrl 1-242 0.75 ± 0.11 
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To investigate whether the two additional Drl homologues in D. melanogaster, Drl-2 and 
Dnt, also bind DWnt5, SPR was used to assess the interactions of their extracellular 
regions with purified DWnt5 (Figure 2.9A and Table 2.2).  The full extracellular region 
of Drl-2 (sDrl-2) displayed a very similar DWnt5-binding affinity to that of sDrl (KD = 
0.15 µM).  The Dnt extracellular region was also found to bind DWnt5, but with a 
reduced affinity (KD = 2.5 µM), approximately four-fold lower than that for sDrl. 
To demonstrate that immobilization of DWnt5 onto CM5 chip surface does not 
significantly alter its binding properties in these studies, the reverse SPR experiments 
were also performed, in which Drl homologs were immobilized onto the CM5 sensorchip 
and purified free DWnt5 was injected (Figure 2.9B&C and Table 2.2). These studies gave 
very similar results, with DWnt5 binding strongly to all three Drl homologs. KD values 
for DWnt5 binding to immobilized sDrl, sDrl-2 and sDnt were 0.10 µM, 0.18 µM and 
0.50 µM, respectively. Compared to the experiments performed with immobilized 
DWnt5, these KD values are relatively lower (suggesting tighter binding), which can 
likely be attributed to the fact that DWnt5 also weakly interacts with the negatively 
charged dextran surface of the CM5 sensorchip (we have observed DWnt5 binding to 
blank CM5 flow cell with high RUs at low micromolar concentrations). 
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Figure 2.9: SPR studies of DWnt5 binding to D. melanogaster Drl homologs. (A) SPR studies used a CM5 
sensorchip on which wildtype DWnt5 protein had been immobilized, and injections of the purified 
extracellular domains of Drl homologs sDrl-2 and sDnt (at the indicated concentrations) were performed in 
comparison to sDrl(1-242).  (B)  In a complementary experiment, SPR studies were performed with the 
extracellular regions of the Drl homologs immobilized on the CM5 chip, and a series of injections of 
wildtype DWnt5 protein at the indicated concentrations. (C)  A representative SPR sensorgram of 
immobilized sDrl binding to DWnt5 (at 160 nM concentration). Colored squares represent actual data 
points. Sensorgram for sDrl immobilized CM5 chip surface is colored red, and sensorgram for mock-
derivatized control sensorchip surface is colored blue. Injection of DWnt5 protein solution starts at ~50 s 
and ends at ~470 s. Injection of regeneration buffer starts at ~830 s and ends at ~980 s. 
 
Table 2.2: SPR studies of Drl homologs binding to DWnt5. Upper table: Drl homologs binding to 
immobilized DWnt5. Lower table: DWnt5 binding to immobilized Drl homologs. 
Analyte Binding KD  (µM) to immobilized DWnt5 
sDrl  0.63 ± 0.08 
sDrl-2 0.15 ± 0.03 
sDnt 2.4 ± 0.2 
 
Immobilized Drl homolog Binding KD  (µM) of wildtype DWnt5 
sDrl  0.10 ± 0.01 
sDrl-2 0.18 ± 0.02 
sDnt 0.50 ± 0.03 
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2.3 Structure Determination of the Derailed-2 Extracellular Region 
In an effort to gain a structural view of a Ryk/Drl family receptor extracellular region, a 
great deal of time and effort was spent trying to crystallize sDrl, but without success.  
However, crystals were obtained for the Drl-2 extracellular region, which has 44% 
sequence identity to sDrl in the WIF domain region, and binds to DWnt5 with similar 
affinity. The sDrl-2 crystals diffracted to 2.2 Å resolution on our home source X-ray 
(Rigaku 007HF with Saturn CCD), and the structure was solved by molecular 
replacement using a truncated poly-alanine model of the NMR structure of human WIF-1 
as search model (Table 2.3).  
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Table 2.3: Derailed-2 extracellular domain crystallographic statistics (molecular 
replacement) 
 
 Drl-2 ectodomain  
Data collection  Rigaku 007HF  
Space group  C2221  
Cell dimensions     
    a, b, c (Å)  56.954   91.615   76.379   
Resolution (Å)  50.00 - 2.25 (2.29-2.25) *  
Rsym or Rmerge  0.054 (0.327)  
I / σI  42.5 (4.4)  
Completeness (%)  99.3 (94.3)  
Redundancy  6.5 (3.5)  
  
Refinement   
Resolution (Å)  50.00 – 2.25  
No. reflections  8664  
Rwork / Rfree  22.0/26.4  
  
Model   
Protein amino acids  aa 26-178  
No. atoms  1292  
    Protein  1209  
    Sugar  42  
    Water  41  
R.m.s. deviations   
    Bond lengths (Å)  0.016  
    Bond angles (º)  2.148  
 
*Values in parentheses are for highest-resolution shell. 
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Similar to hWIF-1, the Drl-2 WIF domain consists of two α helices and nine β 
strands (Figure 2.10A), with overall Cα root mean squared deviation (RMSD) of 2.0 Å 
between these two WIF domains using SSM superimposition (Krissinel and Henrick 
2004). The N-terminal residue Y26 (immediately after the predicted cleavage site for the 
signal peptide) forms the start of strand β1, and the C-terminal tail is located on the 
opposite side of the domain. Two cysteines, C125 and C160, form a conserved disulfide 
bond near the C-terminus that links strands 7 and 9. Clear electron density was 
observed for sugar moieties at two N-linked glycosylation sites (N128 and N148), and 
one O-linked glycosylation site (S171). 
Figure 2.10B shows an overlay of the sDrl-2 WIF domain (cyan) with the hWIF-1 
NMR structure (no lipid bound, red) (Liepinsh, Banyai et al. 2006) and hWIF-1 domain 
crystal structure (lipid bound, yellow) (Malinauskas, Aricescu et al. 2011) using PyMOL 
to minimize RMSD of all matched atoms. The most significant structural difference lies 
in the conformations and positions of the two helices, 1 and 2. For hWIF-1, a 
comparison between the lipid-free NMR structure and the lipid-bound crystal structure 
suggests that binding of phospholipid causes an inward shift of helix α1 relative to that in 
the solution NMR structure, whereas the helix α2 region appear to stretch outwardly to 
accommodate the phospholipid. Unlike hWIF-1, there is no electron density – or space – 
for an embedded phospholipid in our crystal structure of the sDrl-2 WIF domain. 
Nevertheless, the position of helix α1 resembles that seen in the phospholipid-bound 
hWIF-1 structure rather than in the lipid-free NMR structure. On the other hand, the helix 
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α2 region of the sDrl-2 WIF domain most closely matches that seen in the lipid-free 
hWIF-1 NMR structure, despite the fact that this region of sDrl-2 (as well as Ryk/Drl/Dnt) 
is six residues shorter than that in hWIF-1. It is also worth noting that the region 
encompassing α2 and β3 of hWIF-1 appears to be the most flexible part of the NMR 
structure (Liepinsh, Banyai et al. 2006), suggesting that this flexibility is required for 
allowing access of the bound phospholipid. Interestingly, preliminary molecular 
dynamics (MD) simulations of Drl-2 WIF domain suggest similar flexibility in this 
region. 
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Figure 2.10:  Crystal structure of sDrl-2 extracellular domain. (A) Overall crystal structure of sDrl-2. (B) 
Overlay of sDrl-2 WIF domain with hWIF-1 structures. Cyan: crystal structure of sDrl-2 WIF domain, with 
two helices labeled. Red: NMR structure of hWIF-1 (no lipid bound, PDB 2D3J). Yellow: crystal structure 
of hWIF-1 (phospholipid bound, PDB 2YGN). Phospholipid is shown in yellow sticks. 
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In the sDrl-2 crystal structure, a crystallographic dimer is formed that involves 
intimate symmetrical interactions between the surface encompassing helices α1 and α2 of 
one molecule and the same region on its symmetry mate (Figure 2.11A). The binding 
interface is highly hydrophobic, formed by V36, M37, M40, G41, L42, A44 and L46 
around helix α1, together with Y57, A58, F61, T62, P64 and P66 from α2-β3 region, with 
additional polar interactions involving the Q132 and N157 at the periphery of the 
interface. The buried surface area is ~ 300 Å
2
 on each molecule, with a shape 
complementarity of 0.76. Given the high shape complementarity and the fact that most of 
these residues are conserved across Ryk family RTKs (Figure 2.4B), it is possible that 
this interface drives homodimer formation during Ryk/Drl signaling. On the other hand, 
since the same region on the surface of hWIF-1 is postulated to bind the acyl chain of 
Wnt proteins, another intriguing possibility is that this conserved region on Ryk/Drl is 
responsible for Wnt ligand binding – which will be mutually exclusive with this mode of 
dimerization. 
In the crystal, the Ala/Pro-rich C-terminal tail of sDrl-2 lies across the ‗back‘ 
surface of another symmetry mate (Figure 2.11B). It is unclear whether this interaction 
has any physiological relevance for sDrl-2 to carry out its function, or is simply caused 
by crystal packing. A similar sequence is not present in other members of the Ryk/Drl 
family. The seven-residue linker region between the WIF domain and Ala/Pro-rich C-tail 
(residue 164-170) of sDrl-2 is too short to allow the tail to fold back onto its own WIF 
domain. 
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Figure 2.11: Crystal packing of sDrl-2. (A) Packing at the symmetrical interface of the crystallographic 
dimer involving the 1/2 region. (B) Packing of the sDrl-2 C-terminal tail against the WIF domain of 
another symmetry mate. 
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2.4 Structure-Guided Point Mutations in the Derailed Extracellular Region 
Disrupt its Binding to DWnt5 
Due to the high sequence similarity between the sDrl and sDrl-2 WIF domains (44% 
identical), most of the features observed in the sDrl-2 crystal structure are very likely also 
to be present in sDrl. Using the sDrl-2 structure as a template, I built a homology model 
of the sDrl WIF domain using the SWISS-MODEL server (Figure 2.12) (Arnold, Bordoli 
et al. 2006). The model has a QMEAN4 global score of 0.661 and a Z-score of -1.45, 
indicating a high level of confidence in model reconstruction (Benkert, Biasini et al.). A 
surface conservation analysis was then conducted on the structural model of the sDrl WIF 
domain, using ClustalW sequence alignment of Drl sequences from eight invertebrate 
species as template (Figure 2.12A, see Experimental Procedures for details). Surface 
residues in the structural model are colored based upon their conservation in the 
alignment: red colored regions indicate high conservation, whereas white colored regions 
indicate low conservation. The three N-glycosylation sites are colored green. Among all 
surface exposed areas, the surface shown in the lower right part of Figure 2.12A stands 
out as the most conserved area within the Drl WIF domain (and it is not blocked by N-
linked glycosylation sites). A closer look (Figure 2.12B) at this surface area identifies the 
conserved residues involved, which can be divided into three regions: E40, L41, Y42, 
K45 and E46 around strand β2 (region 1, colored green); I49, N50, Y52, A53, N55, F56, 
V58, P59 and P61 on the helix α2/strand β3 segment (region 2, colored orange); E126, 
K152 and I154 form the third region (region 3, colored yellow). These residues are also 
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among the most conserved residues between WIF domains of Drl homologs (Figure 
2.4B).  
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Figure 2.12: Surface conservation of Drl WIF domain homology model. (A) Illustration of surface 
conservation of the Drl WIF domain. The most conserved residues are colored red and the least conserved 
residues are colored white. The three N-glycosylation sites are colored green. (B) Stick and ribbon 
representation of the conserved residues in the structural model of Drl WIF domain. The model orientation 
is the same as the lower right figure in (A).  
As mentioned in the previous section, the rather hydrophobic region around 
helices 1 and 2 forms the interface of a crystallographic homodimer in our crystal 
structure of sDrl-2. High evolutionary conservation also suggests that it may be 
responsible for binding to Wnt proteins. To test the latter possibility, point mutations 
were introduced into each area of sDrl, and the resulting variants were tested for their 
ability to bind DWnt5 using SPR assays (Figure 2.13 and Table 2.4). Any mutation in 
region 2 (Y52E, F56E and V58E: orange) – in the α2/β3 segment – abolished binding of 
sDrl to DWnt5. An E40K mutation in region 1 (green) also decreased binding affinity to 
DWnt5 by ~10 fold. The other two mutations in region 1, L41E and Y42E, caused 
aggregation of sDrl during gel filtration, so their effects on DWnt5 binding could not be 
characterized. By contrast with these examples, mutations in region 3 of sDrl (E126K and 
I154E: yellow) had no effect on DWnt5 binding affinity. Therefore, the segment 
encompassing helices α2 and strand β3 (region 2) on sDrl appears to be responsible for 
DWnt5 binding, with hydrophobic residues in the segment (Y52, F56, V58) being 
implicated.  E40 in Region 1 (at the beginning of strand 2) may also contribute to 
DWnt5 binding. 
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Figure 2.13: SPR studies to characterize the effect of point mutations in sDrl (1-242) on binding to 
immobilized DWnt5 wildtype protein.  
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Table 2.4: SPR studies of DWnt5 binding property of Drl ectodomain proteins (residue 1-242) with single 
point mutation. 
Analyte Binding KD  (µM) to immobilized DWnt5 
sDrl wildtype 0.63 ± 0.09 
sDrl E40K 6.1 ± 0.3 
sDrl L41E Aggregation in solution 
sDrl Y42E Aggregation in solution 
sDrl Y52E 47 ± 13 
sDrl F56E 99 ± 142 
sDrl V58E 69 ± 19 
sDrl E126K 0.67 ± 0.07 
sDrl I154E 0.62 ± 0.08 
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2.5 Summary and Discussion of Derailed-DWnt5 Studies 
In this study, I have characterized the interaction between Derailed family receptor 
tyrosine kinases and its ligand, DWnt5, in vitro using purified proteins. I have shown, for 
the first time, that Ryk/Drl family proteins‘ extracellular region binds directly to a Wnt 
ligand. The DWnt5 binding affinities (KD) of Drl homologs lie in the range of 100 nM to 
low micromolar as determined by SPR. A crystal structure of sDrl-2 has revealed 
important features of the WIF domains of Drl family proteins. Based on the structure, the 
region on the Drl WIF domain that is responsible for DWnt5 binding has been mapped 
using site-directed mutagenesis and SPR assays. The residues implicated form a ring 
around a depression that lies between the two -helical regions, suggesting that this is the 
key ligand-binding site. 
Given the high sequence homology within the mammalian and Drosophila 
Ryk/Drl family and Wnt family, the interaction mode and binding interface of Drl-
DWnt5 characterized here are likely to be conserved in the case of human Ryk-Wnt 
interactions. Unfortunately, due to experimental difficulties in generating useful 
quantities of the soluble Ryk extracellular region and human Wnt proteins in detergent-
free conditions, similar biophysical studies have not proven possible using this strategy.  
Previous studies in the literature have attempted to measure the interaction 
affinities between Wnt proteins and their cell surface receptors such as Frizzled, Ror and 
Ryk using cell-based or ELISA assays. Most of those studies have reported KD values in 
the low nanomolar range. For example, Liu et al. (Liu, Shi et al. 2005) reported a KD 
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value of 8 nM for binding of human Wnt1 to cell surface-expressed Ryk. Using a similar 
cell-based overlay assay and a Wnt3/alkaline phosphatase fusion protein, Schmitt et al. 
(Schmitt, Shi et al. 2006) also measured Wnt3 – Ryk interaction with an apparent KD 
value of 4 nM. These reported values are more than an order of magnitude lower 
(suggesting tighter binding) than that of the Drl-DWnt5 interaction which I have 
determined in SPR assays.  This is a common observation in studies of cell surface 
receptors.  For example, although cellular studies of EGF binding to its receptor yield KD 
values in the low nanomolar (6-12 nM) range (Burgess, Cho et al. 2003), studies of EGF 
binding to the isolated extracellular region of its receptor typically yield well-validated 
KD values in the 100-200 nM range (Dawson, Berger et al. 2005) – revealing a similar 
difference of an order of magnitude as seen in my DWnt5 studies.  These differences can 
arise for several reasons, and are not likely to reflect any intrinsic difference between the 
binding properties of Drl and DWnt5 when compared with other receptor/Wnt complexes.  
If Wnt binding induces receptor dimerization, this dimerization will be favored in the 
membrane context compared with solution – and the resulting linked equilibria will yield 
a higher apparent Wnt binding affinity for cellular assays. The differences might also 
reflect the different assay systems employed. For example, the detection antibodies 
employed in the cell-based or ELISA-based studies (for measuring the amount of bound 
protein) frequently cause self-association of both receptor and ligand, which will at the 
same time increase the avidity (and therefore apparent affinity) of binding. Alternatively, 
the differences might reflect the presence of other cellular factors that contribute to 
complex formation. Extracellular ligands such as Wnt proteins commonly display weak 
interactions with the sugars, proteoglycans, and (since they are acylated) hydrophobic 
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membranes present on the surface of cells. Interactions of this sort would contribute to 
the increased binding affinity observed in cellular studies. In addition, the presence of a 
co-receptor cannot be ruled out. 
It is intriguing to postulate what might happen after binding of Wnt to Ryk/Drl on 
the cell surface. Ryk/Drl contain an intracellular pseudokinase domain that has no 
observable kinase activity, even when they are clustered (and oligomerized) onto lipid 
vesicles (my unpublished results). If the intracellular domains of Ryk/Drl have no 
catalytic function, they must initiate downstream signaling through as-yet-unknown 
signaling mechanism, which (in the absence of kinase activity) sets them apart from other 
RTKs. Unlike seven transmembrane domain proteins such as like GPCRs, the 
cytoplasmic region of Ryk/Drl is linked to extracellular Wnt binding through a single 
transmembrane domain, making it unlikely that a ligand-induced conformational change 
could be propagated across the membrane without either ligand-induced dimerization or 
association (heterodimerization) with some other cell-surface molecules – which could be 
other Wnt receptors, for example. 
Several studies have already suggested that Wnt ligands can bind simultaneously to 
Ryk and other cell surface receptors. For example, a Ryk/Wnt/Frizzled complex can be 
co-immunoprecipitated (Lu, Yamamoto et al. 2004), indicating the formation of ternary 
complex. In addition, the soluble Ryk extracellular region blocks Wnt binding to cell-
surface Ryk, but not to Frizzleds – whereas secreted Frizzled-like proteins block Wnt 
binding to cell-surface Frizzled but not to Ryk (Schmitt, Shi et al. 2006). Thus, the basis 
for Wnt binding to these classes of receptor appears to be different, suggesting different 
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Wnt recognition properties for the WIF and CRD domains. Ryk has also been shown to 
co-immunoprecipitate with receptors EphB2 and EphB3 (Halford, Armes et al. 2000; 
Trivier and Ganesan 2002; Kamitori, Tanaka et al. 2005). Taken together, these data 
suggest that Wnt binding may brings Ryk/Drl into close proximity with other cell 
receptors, with which it collaborates in promoting intracellular signaling.   
Many important questions remain to be addressed concerning the Ryk/Drl-Wnt 
signaling system. For the next steps of this study, key goals will include the following: 
1. Structural characterization of Wnt proteins using X-ray crystallography and 
hydrogen/deuterium (H/D) exchange, and identification of the region(s) 
responsible for binding to Ryk/Drl. 
2. Addressing the cellular signaling effects of Ryk/Drl-Wnt when binding-defective 
mutations are introduced. 
3. Determining the stoichiometry of the Ryk/Drl-Wnt complex, and assessing 
whether DWnt5 binding induces dimerization of Ryk/Drl extracellular regions. 
4. Understanding the signaling mechanisms of Wnt-bound Drl/Ryk. 
At present, the only structural information of Wnt family protein comes from the 
crystal structural of XWnt8 in complex with a mouse Frizzled-8 CRD domain with which 
it was co-expressed; this co-expression was required for production of soluble XWnt8. 
Unlike other Wnts, DWnt5 can be purified in large quantities and is well-behaved in 
solution without detergents – making it a promising candidate for crystallographic studies 
to provide further structural information of Wnt proteins.  In particular, since the only 
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Wnt structure known is bound to a Frizzled CRD, it will be important to determine a 
structure of a free Wnt protein. Additionally, a co-crystal structure of DWnt5 with sDrl 
(or other sDrl homologs) will greatly help our understanding of their binding mode. 
Alternatively, in the absence of a DWnt5 crystal structure, H/D exchange method coupled 
with mass spectrometry can offer important structural insights regarding the structural 
dynamics of Wnt domain and also likely identify DWnt5 segments that are responsible 
for Drl binding when it is performed with DWnt5-Drl complex.  
Albeit soluble, mature wildtype DWnt5 protein has heterogeneous N-terminal start 
sites as well as a long, 150 amino acids insert in the Wnt domain. These properties 
introduce potential structural heterogeneity and instability for further biophysical 
characterization, especially protein crystallography. Several strategies are being 
employed in order to improve current DWnt5 protein construct for crystallography 
purposes: 
1. Replacing the long Wnt domain insert with a short 6xHis tag, which serves two 
purposes: (a) removing the loop to improve protein homogeneity and stability, 
and (b) allowing an additional purification step using NiNTA resin. Removal of 
this region should have minimal effect on Wnt domain integrity since (a) most of 
Wnt5 homologs found in other species do not have such an insert and (b) the 
DWnt5ΔB construct fully retains sDrl binding affinity and has better expression. 
2. Introducing a TEV protease cleavage site in between residue 470-540 to remove 
the extra N-terminal non-conserved residues and to improve protein homogeneity. 
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This region is in between the poly-serine segment (and N-terminal start of mature 
DWnt5) 455-SQPSISSSSSS-465 and the Wnt domain. 
With completion of the goals summarized above, the insights I have gained into Wnt 
signaling through Drl proteins will be further developed towards a mechanistic 
understanding of this important signaling axis. 
2.6 Experimental Procedures for Chapter 2 
Expression and Purification of sDrl and DWnt5 Proteins 
For sDrl expression, DNA encoding 6xHis tagged Drl full extracellular region (1-242) 
was cloned into pFastBac1 using 5‘-GAATGGATCCAACATGGCCCCCAACTTGCTAACAA 
TCGGATTAC-3‘ as forward primer and 5‘-GAATCTCGAGTTAGTGATGGTGATGGTGATG 
GCCACTGGCCGGTGGCACCAG-3‘ as reverse primer. Recombinant baculoviruses were 
generated using the Bac-to-Bac system (Invitrogen). For protein expression, Sf9 medium 
was harvested three days post infection and subjected to extensive dialysis at 4 ˚C. 
Proteins were then extracted from medium using self-packed NiNTA resin. NiNTA resin 
was washed twice with low imidazole buffer (20 mM HEPES pH 7.5, 150 mM NaCl and 
15 mM imidazole) and sDrl protein was then eluted from NiNTA resin with buffer 
containing 20 mM HEPES pH 7.5, 150 mM NaCl and 100 mM imidazole.  sDrl protein 
was further purified using an UnoQ anion exchange column (BioRad) (loading buffer 
was 20 mM HEPES pH7.5 and 70 mM NaCl, with an elution gradient of 70 mM -1 M 
NaCl) and a Superose 12 sizing column (GE Healthcare) (running buffer: 10mM HEPES 
pH 7.5 and 150mM NaCl), with a final yield of ~ 1mg/liter of medium. All purifications 
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were performed at room temperature. Other sDrl variants are purified in the same way. 
pFastBac1 plasmids containing either sDrl-2 or sDnt were obtained from Dr. Lee Fradkin. 
Both constructs contain ORF encoding full extracellular regions of either Drl-2 or Dnt 
with native signal peptide and a C-terminal RPLESRGPFEGKPIPNPLLGLDSTR 
TGHHHHHH sequence. 
For expression of DWnt5 protein, S2 cells were stably transfected with a mixture 
of three plasmids (i) pUAST-DWnt5, (ii) pAc-Gal4 and (iii) pCoHygro (10g:10g:1g) 
using calcium phosphate method, and were selected in Schneider‘s medium (Sigma) 
supplemented with 10% fetal calf serum (Sigma, Cat#F0643) and 300 g/ml hygromycin 
(cellgro) for 3 weeks. Schneider‘s cell medium was then replaced with EXCELL 420 
serum-free medium (SAFC Biosciences) for subsequent cell culture, and constitutive 
secretion of DWnt5 into the medium was verified using DWnt5 specific antibodies 
(Fradkin, Noordermeer et al. 1995). Binding of Gal4 protein (constitutively expressed 
from pAc-Gal4 vector) to the promoter region of pUAST-DWnt5 induces high-level 
expression of DWnt5 protein in S2 cells. For large scale DWnt5 expression, cells were 
seeded at 4x10
6
 cells/ml in spinner flasks. After 5 days of growth, medium (~3 litres) was 
harvested and flowed through 4ml Fractogel SO3 (EMD) resin at 4˚C. Then SO3 resin 
was washed twice with 10ml of wash buffer (20 mM HEPES pH 7.5, 250 mM NaCl). 
DWnt5 was then eluted from SO3 column with three washes of 4ml elution buffer (20 
mM HEPES pH 7.5, 900 mM NaCl). Protein solution was then diluted with 3 volumes of 
20 mM HEPES pH7.5 buffer to lower the NaCl concentration to <250 mM. All 
subsequent purification steps were performed at room temperature. The protein sample 
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was next loaded onto a self-packed 2ml Fractogel SO3 FPLC column pre-equilibrated 
with 20 mM HEPES pH7.5 and 150 mM NaCl. A gradient from 150 mM – 1 M NaCl 
was then used to elute the bound DWnt5 protein from the column (elution peak around 
650mM NaCl). Eluted fractions were then diluted again with 3 volumes of 20 mM 
HEPES pH7.5 buffer, loaded onto CHT2 column (BioRad) equilibrated with buffer 
containing 20 mM HEPES pH7.5, 150 mM NaCl, 2.5 mM NaH2PO4, 2.5 mM K2HPO4.  
A 0-100% gradient of Buffer B (250 mM NaH2PO4, 250 mM K2HPO4 and 150 mM NaCl) 
was used to elute the protein. Finally, eluted fractions were pooled together, concentrated, 
and loaded onto a Superose 6 column (GE Healthcare) with running buffer containing 10 
mM HEPES pH 7.5 and 150 mM NaCl. The purified protein could be flash frozen in the 
presence of 10% glycerol with no significant aggregation or loss of sDrl-binding activity 
upon thawing. 
Pull-down of DWnt5 by Drl Extracellular Regions 
EXCELL 420 serum-free S2 medium containing secreted DWnt5 was concentrated by 
10-fold in an Amicon concentrator. The purified recombinant Drl extracellular region 
(sDrl) was added at a 1 µM final concentration to 1.2 ml of concentrated S2 medium, and 
incubated for 2 hours at 4 ˚C. Then, 60 µl of pre-washed NiNTA bead slurry (enough to 
bind all the added 6xHis-tagged sDrl) was added to the solution for an additional hour at 
4 ˚C. Supernatant and beads were then separated and NiNTA beads were resuspended in 
buffers (20 mM HEPES pH7.5, 150 mM NaCl) to make samples for Western blotting 
using rabbit anti-DWnt5 polyclonal Ab (epitope B, (Fradkin, Noordermeer et al. 1995)) 
and mouse anti-His5 Ab (QIAGEN).  
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Surface Plasmon Resonance Studies 
SPR experiments were performed using a Biacore3000 instrument (GE). DWnt5 protein 
was immobilized onto a CM5 sensorchip using the amine coupling method as 
recommended by the manufacturers. Briefly, purified DWnt5 protein was diluted in 
HBS-EP buffer (10 mM HEPES pH7.5, 150 mM NaCl, 3 mM EDTA, 0.005% 
Polysorbate 20) to a final concentration of 1 µM and allowed to flow across an 
EDC/NHS-activated CM5 chip surface at 5 µl/min for a total volume of 100 µl. The 
sensorchip surface was then quenched with an injection of 1M ethanolamine pH 8.0. 
Typically, about 10000 RU of DWnt5 was immobilized onto the surface. DWnt5 
sensorchips were relatively stable in a short term (1-2 weeks), as determined by tests of 
sDrl binding, when stored at 4 °C, but tended to lose sDrl binding affinity and capacity 
(in terms of both KD and Bmax) over time.  
For sDrl binding experiments, 10 samples of purified, serially diluted (1:1 in 
HBS-EP) sDrl proteins (20 µM - 4 nM) were prepared. Then samples were sequentially 
injected at room temperature, starting from the lowest concentration. For each injection, 
steady state binding of protein was achieved, and bound sDrl proteins were then allowed 
to spontaneously detach from the sensorchip surface after each injection in HBSEP 
running buffer. An example sensorgram, including the dissociation phase, is shown in 
Figure 2.8B.  In a typical case, the SPR signal fell to with 20 RUs of that measured 
before ligand injection by the end of the dissociation phase (typically 5 minutes).  RUs 
recorded from steady state binding at each concentration were then used to fit the sDrl 
binding curve to a simple hyperbola using Prism software. 
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For the reverse experiment (immobilizing sDrl homologs and flowing DWnt5 
protein across the Drl-derivatized surfaces), 25 µM of purified extracellular regions of 
Drl homologs (in 8 mM HEPES pH 7.5, 120 mM NaCl, 10% glycerol) were diluted 1:4 
in  10mM sodium acetate (pH 4.5) solution and flowed across an activated CM5 
sensorchip surface at 10µl/min for 9 minutes. About 10000 - 14000 RUs of each Drl 
homolog were immobilized onto the surface. Purified DWnt5 protein was then injected 
on to the sensor chip (concentrations from 10 nM to 5 µM), and was allowed at each 
injection to reach steady state binding (typically 10µl/min for 7 minutes). A typical 
sensorgram is shown in Figure 2.9C. 25µl of regeneration buffer (10 mM sodium acetate 
pH4.5 and 500 mM NaCl) was then used to wash off bound DWnt5 proteins from the 
CM5 surface after each injection, bringing the SPR signal after each experiment down to 
within 10% of the maximal binding RU of that injection. Other aspects of the 
experimental setup are similar. 
Crystallography and Structural Determination of sDrl-2 
sDrl-2 full extracellular region (1-183) with a C-terminal Factor Xa (FXa) cleavage site 
(IEGR), spacer peptide (ASGPFEGKPIPNPLLGLDSTRTG) and 6xHis tag was subcloned 
into pFastBac1 vector and expressed in Trichoplusia ni cells using baculovirus infection 
and ESF921 medium (ExpressionSystems). Cell-conditioned medium was collected and 
passed through a NiNTA column. The column was then washed twice with low imidazole 
buffer (20 mM HEPES pH 7.5, 150 mM NaCl and 15 mM imidazole) and sDrl2 protein 
was eluted from NiNTA bead with buffer containing 20 mM HEPES pH 7.5, 150 mM 
NaCl and 100 mM imidazole. After buffer exchange to remove imidazole, FXa protease 
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was used to cleave the 6xHis tag from the protein (10 µg protease for 1 mg purified sDrl-
2 in 1 ml solution for 1 hour at room temperature). Cleaved sDrl-2 protein was then 
passed through a Superose 12 sizing column (GE Healthcare) equilibrated with gel 
filtration buffer (10 mM HEPES pH 7.5, 150 mM NaCl) at room temperature. Protein at 
the major peak was collected, partially deglycosylated with PNGaseF (New England 
BioLabs) (2,000 Unit/mg of sDrl-2 protein) for 3 hours at room temp and concentrated to > 
12 mg/ml for crystallization. Crystals were grown at 21˚C using the hanging drop vapor 
diffusion method by mixing 1 µl protein solution with 1 µl well solution containing 100 
mM Tris pH 8.5, 25% PEG 6000, 100 mM Sodium Acetate and 15% glycerol. Crystals 
formed within 2 days and were frozen directly in liquid nitrogen. Data were collected 
using a home source X-ray unit (Rigaku), and were processed using HKL2000 software 
(Otwinowski and Minor 1997).  Initial phasing was obtained by molecular replacement 
using a truncated poly-alanine model of the NMR structure of human WIF-1(PDB: 2D3J) 
(Liepinsh, Banyai et al. 2006) as the search model in Phaser (CCP4 (Collaborative 
Computational Project Number 4) 1994). Structural refinement and model building were 
carried out using Refmac (CCP4 (Collaborative Computational Project Number 4) 1994) 
and Coot (Emsley and Cowtan 2004). Structure figures were generated using PyMol 
(DeLano 2002). 
Homology Modeling and Surface Conservation Analysis of Drl WIF Domain 
Homology model of Drl WIF domain was built using the SWISS-MODEL server (Arnold, 
Bordoli et al. 2006) based on the crystal structure of sDrl-2 ectodomain. Surface 
conservation analysis was conducted based on alignment of Drl protein sequences from 
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eight invertebrate species: GI17137162 (Drosophila melanogaster), GI194759318 
(Drosophila ananassae), GI195049987 (Drosophila grimshawi), GI195115220 
(Drosophila mojavensis), GI157130072 (Aedes aegypti), GI91092648 (Tribolium 
castaneum), GI328789866 (Apis mellifera) and GI156547777 (Nasonia vitripennis). 
Illustration of surface conservation was generated using UCSF Chimera software 
(Pettersen, Goddard et al. 2004). 
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Appendix 1 List of Kinase Inhibitors Used in Chapter 1.2.3  
(Calbiochem  Cat. # 539744) 
ID Plate 
Location 
Catalog 
Number 
Product Description CAS 
Number 
PubChem 
Compound 
ID# 
1 A1 DMSO       
2 A2 121767  AG 1024 65678-07-1 2044  
3 A3 121790  AGL 2043 226717-28-8 9817165  
4 A4 124011  Akt Inhibitor IV 681281-88-9 5719375  
5 A5 124012  Akt Inhibitor V, Triciribine 35943-35-2 290486  
6 A6 124018  Akt Inhibitor VIII, Isozyme-
Selective, Akti-1/2 
612847-09-3 10196499  
7 A7 124020  Akt Inhibitor X 925681-41-0 16760284  
8 A8 521275  PDK1/Akt/Flt Dual Pathway 
Inhibitor 
331253-86-2 
and                 
329710-24-9 
5113385  
9 A9 189404  Aurora Kinase Inhibitor II 331770-21-9 6610278  
10 A10 197221  Bcr-abl Inhibitor 778270-11-4 5311510  
11 A11 203290  Bisindolylmaleimide I 133052-90-1 2396  
12 A12 BLANK       
13 B1 DMSO       
14 B2 203297  Bisindolylmaleimide IV 119139-23-0 2399  
15 B3 203696  BPIQ-I 174709-30-9 2427  
16 B4 220285  Chelerythrine Chloride 3895-92-9 72311  
17 B5 234505  Compound 56 171745-13-4 2857  
18 B6 260961  DNA-PK Inhibitor II 154447-35-5 9860529  
19 B7 260962  DNA-PK Inhibitor III 404009-40-1 9859309  
20 B8 528100  PI-103 371935-74-9 9884685  
21 B9 266788  Diacylglycerol Kinase 
Inhibitor II 
120166-69-0 657356  
22 B10 317200  DMBI 5812-07-7 5353593  
23 B11 324673  EGFR/ErbB-2 Inhibitor 179248-61-4 9843206  
24 B12 BLANK       
25 C1 DMSO       
26 C2 324674  EGFR Inhibitor 879127-07-8 9549299  
27 C3 324840  EGFR/ErbB-2/ErbB-4 
Inhibitor  
881001-19-0 11566580  
28 C4 343020  Flt-3 Inhibitor 301305-73-7 1048845  
29 C5 343021  Flt-3 Inhibitor II 896138-40-2 11601743  
30 C6 344036  cFMS Receptor Tyrosine 870483-87-7 11617559  
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Kinase Inhibitor 
31 C7 365250  Gö 6976  136194-77-9 3501  
32 C8 365251  Gö 6983 133053-19-7 3499  
33 C9 371806  GTP-14564 34823-86-4 3385203  
34 C10 375670  Herbimycin A, 
Streptomyces sp. 
70563-58-5 16760502  
35 C11 343022  Flt-3 Inhibitor III 852045-46-6 11772958  
36 C12 BLANK       
37 D1 DMSO       
38 D2 407248  IGF-1R Inhibitor II 196868-63-0 9549305  
39 D3 407601  IRAK-1/4 Inhibitor 509093-47-4 11983295  
40 D4 420099  JAK Inhibitor I 457081-03-7 5494425  
41 D5 420104  JAK3 Inhibitor II 211555-04-3 3795  
42 D6 420121  JAK3 Inhibitor IV 58753-54-1 176406  
43 D7 420126  JAK3 Inhibitor VI 856436-16-3 16760524  
44 D8 428205  Lck Inhibitor 213743-31-8 6603792  
45 D9 440202  LY 294002 154447-36-6 3973  
46 D10 440203  LY 303511 154447-38-8 3971  
47 D11 448101  Met Kinase Inhibitor 658084-23-2 9549297  
48 D12 BLANK       
49 E1 DMSO       
50 E2 513035  PD 158780 171179-06-9 4707  
51 E3 513040  PD 174265 216163-53-0 4709  
52 E4 521231  PDGF Receptor Tyrosine 
Kinase Inhibitor II 
249762-74-1 5330548  
53 E5 521232  PDGF Receptor Tyrosine 
Kinase Inhibitor III 
205254-94-0 10907042  
54 E6 521233  PDGF Receptor Tyrosine 
Kinase Inhibitor IV 
627518-40-5 9797370  
55 E7 521234  PDGF RTK Inhibitor 347155-76-4 16760609  
56 E8 527450  PKR Inhibitor 608512-97-6 6490494  
57 E9 527455  PKR Inhibitor, Negative 
Control 
852547-30-9 16760619  
58 E10 528106  PI 3-Kg Inhibitor  648450-29-7 5289247  
59 E11 528108  PI 3-KbInhibitor II  648449-76-7 5287855  
60 E12 BLANK       
61 F1 DMSO       
62 F2 529574  PP3 5334-30-5 4879  
63 F3 529581  PP1 Analog II, 1NM-PP1 221244-14-0 5154691  
64 F4 539652  PKCbII/EGFR Inhibitor 145915-60-2 6711154  
65 F5 539654  PKCb Inhibitor 257879-35-9 6419755  
66 F6 553210  Rapamycin 53123-88-9 16760631  
67 F7 555553  Rho Kinase Inhibitor III, 
Rockout 
7272-84-6 644354  
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68 F8 555554  Rho Kinase Inhibitor IV not registered 16760635  
69 F9 539648  Staurosporine, N-benzoyl- 120685-11-2 16760627  
70 F10 567805  Src Kinase Inhibitor I 179248-59-0 1474853  
71 F11 572660  SU11652 326914-10-7 5329103  
72 F12 BLANK       
73 G1 DMSO       
74 G2 574711  Syk Inhibitor 622387-85-3 6419747  
75 G3 574712  Syk Inhibitor II 227449-73-2 16760670  
76 G4 574713  Syk Inhibitor III 1485-00-3 672296  
77 G5 616451  TGF-b RI Kinase Inhibitor 396129-53-6 447966  
78 G6 616453  TGF-b RI Inhibitor III 356559-13-2 16079009  
79 G7 658390  AG 9  2826-26-8 2063  
80 G8 658401  AG 490 133550-30-8 5328779  
81 G9 658440  AG 112 144978-82-5 5328804  
82 G10 658550  AG 1295 71897-07-9 2048  
83 G11 658551  AG 1296 146535-11-7 2049  
84 G12 BLANK       
85 H1 DMSO       
86 H2 658552  AG 1478 175178-82-2 2051  
87 H3 676480  VEGF Receptor 2 Kinase 
Inhibitor I 
15966-93-5 6419834  
88 H4 676481  VEGF Receptor Tyrosine 
Kinase Inhibitor II 
269390-69-4 9797919  
89 H5 676482  VEGF Receptor Tyrosine 
Kinase Inhibitor III, KRN633 
286370-15-8 9549295  
90 H6 676485  VEGF Receptor 2 Kinase 
Inhibitor II 
288144-20-7 5329155  
91 H7 676487  VEGF Receptor 2 Kinase 
Inhibitor III 
204005-46-9 5329098  
92 H8 676489  VEGF Receptor 2 Kinase 
Inhibitor IV 
216661-57-3 5329468  
93 H9 260964  DNA-PK Inhibitor V 404009-46-7 16760391  
94 H10 189405  Aurora Kinase Inhibitor III 879127-16-9 9549303  
95 H11 569397  Staurosporine, 
Streptomyces sp. 
62996-74-1 451705  
96 H12 BLANK       
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Appendix 2 A Chemical Genetic Approach to Study ErbB Signaling in Cells 
As shown in Chapter 1.4, the kinase inactivating mutations of ErbB3 have shown little 
effect on ligand induced ErbB autophosphorylation in BaF3 cells or Akt activation in 
CHO cells, arguing that kinase activity of ErbB3 does not directly contribute to these 
cellular signaling. However, it is still possible that ErbB3 kinase participate in other 
signaling events that are not investigated in our cellular studies. One common strategy to 
study the cellular signaling of kinases is to use specific kinase inhibitors. However, this 
standard approach is impossible for our study since there is no ErbB3 kinase-specific 
inhibitor currently available. We have also discussed in Chapter 1 about the possibility 
that ErbB3 kinase may have distinct substrates other than the phosphorylation sites 
examined in our study. Therefore, we need to look for potential substrates of ErbB3 
kinase in cells. However, historically it has been very difficult to track direct substrate of 
kinases in a cellular content.  
To overcome these problems, the Shokat lab at U.C.S.F has developed a chemical 
genetic approach using a group of specific ATP analogs, which cannot be effectively 
accommodated by wildtype kinases, as either inhibitors (bumped inhibitors) or substrate 
phosphate donors (bumped ATPs) for rationally engineered kinases (Figure 1) (Elphick, 
Lee et al. 2007). Removing the side chain of a ‗gatekeeper‘ residue in the ATP binding 
site of kinase creates extra space for the engineered kinase to bind these ATP analogs 
(without disrupting intrinsic kinase activity). The engineered kinase is therefore called 
analog-sensitive (AS) kinase. There are two classes of ATP analogs: (1) ‗bumped ATPs‘, 
in which a bulky group is attached onto the N6 position of ATP, that can be used as ATP 
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substrate by AS kinases; and (2) membrane-permeable ‗bumped inhibitors‘, in which 
bulky groups are attached onto adenine scaffold, that serve as specific inhibitors for AS 
kinases. Ideally, these bumped ATP/bumped inhibitors will only affect the function of 
engineered kinases with analog-sensitive mutation, but not the activity of corresponding 
wildtype kinase (Figure 1).  
With this chemical genetic approach, I have attempted to dissect the cellular 
signaling role of ErbB3 using bumped ATP/bumped inhibitors on analog-sensitive ErbB3 
mutant (and using wildtype ErbB3 as a control group). As shown in the main text, full 
length ErbB3 with analog sensitive mutation (T768G) fully retains signaling ability of 
ligand induced ErbB autophosphorylation (in BaF3 cells, Figure 1.10A) and Akt 
activation (in CHO cells, Figure 1.11), suggesting that its signaling function is intact. 
Unfortunately, the analog-sensitive mutation (T768G) causes aggregation of recombinant 
protein of ErbB3 kinase overexpressed in sf9 cells, which makes it difficult to directly 
characterize the effect of bumped ATP/bumped inhibitors on analog sensitive ErbB3 
kinase mutant in vitro. To circumvent this problem, homologous EGFR kinase has been 
used as a model system to validate this approach since the equivalent analog-sensitive 
mutation (T766G) is well tolerated in recombinant EGFR intracellular protein and does 
not affect its solubility/activity. The preliminary studies with EGFR have yielded some 
encouraging results, and warrant further investigation of ErbB signaling using this 
approach. 
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Figure 1: Diagram of the chemical genetic approach to study cellular signaling of kinases. (A) Due to the 
steric hindrance of ATP binding pockets, wildtype kinases cannot bind effectively to ‗bumped inhibitors‘ or 
‗bumped ATPs‘. (B) Mutating the gatekeeper residue in the kinase of interest results in a analog-sensitive 
kinase that can effectively utilize the ‗bumped ATPs‘ or bind to ‗bumped inhibitors‘ with high affinity. 
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2.1 Using Bumped Inhibitors to Selectively Inhibit Cellular Signaling by Analog-
sensitive ErbB Mutant. 
Due to the lack of inhibitors specific for wildtype ErbB3 kinase, we investigated whether 
bumped inhibitors can serve as specific inhibitors for analog-sensitive (T768G) ErbB3 in 
cellular studies. We have obtained four membrane-permeable bumped inhibitors from the 
Shokat lab (1-NA-PP1, 1-NM-PP1, 2-NA-PP1 and 2-NM-PP1). Their chemical structures 
are shown in Figure 2A. The ideal bumped inhibitor shall selectively inhibit analog-
sensitive kinase mutant in the assay and at the same time have minimal influence on the 
activity of wildtype kinase. Since ErbB3 signaling requires other ErbB kinases in the 
heterodimer, a successful candidate inhibitor for my study shall not inhibit any wildtype 
ErbB kinases (not only ErbB3 kinase).  
Thus, before applying the bumped inhibitors in the cellular assays, we need to 
first make sure that (1) bumped inhibitors only binds to analog-sensitive ErbB3 kinase 
but not wildtype ErbB3 kinase; and (2) bumped inhibitors do not compromise the kinase 
activity of other ErbB family RTKs (especially ErbB2) that form heterodimer with ErbB3. 
Unfortunately,  recombinant proteins of either wildtype ErbB2 kinase domain or T768G-
mutated ErbB3 kinase domain form total aggregates when overexpressed in sf9 cells, 
which prevents the characterization of their binding to bumped inhibitors in vitro. 
Therefore, we cannot directly test whether both conditions (1) and (2) are fully satisfied 
in our chemical genetic approach. On the other hand, both wildtype and analog-sensitive 
(T766G) EGFR kinase domains can be easily purified as recombinant protein. Therefore, 
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we decided to use EGFR kinase as a model for testing the effect of bumped inhibitors on 
ErbB family kinases. 
Using an in vitro radioactive [γ-32P]ATP kinase assay, we have investigated 
whether the bumped inhibitors can selectively inhibit analog-sensitive EGFR kinase but 
not wildtype EGFR kinase. 10µM of each inhibitor is used in the kinase assay with 
purified recombinant EGFR kinases and the kinase activity is monitored as incorporation 
of 
32
P into substrates (Figure 2B). The results suggest that, while all four inhibitors are 
able to inhibit analog-sensitive (T766G) EGFR kinase, three of them are also strong 
inhibitor for wildtype EGFR kinase. Only 2-NM-PP1 meets our criteria of a selective 
inhibitor for analog sensitive ErbB kinase, and it will be used in our subsequent cellular 
assays.  
131 
 
 
132 
 
Figure 2: Inhibitory effect of bumped inhibitors on EGFR kinases. (A) Chemical structures of bumped 
inhibitors (Bishop, Kung et al. 1999). (B) Selectivity of bumped inhibitors to EGFR kinase (wildtype or 
analog-sensitive). In the kinase assays, 0.5 µM EGFR kinase domain (wildtype or T766G) is incubated 
with 100 µM ATP, ~1 µCi [γ-32P]ATP, 200 µM poly GluTyr peptide substrate, 5 mM MgCl2 and 10 µM 
indicated inhibitor or DMSO control (-) for 5 minutes at room temperature. The reactions are stopped with 
100mM EDTA and spotted onto nitrocellulose paper for washing and scintillation counting to measure the 
incorporation of 
32
P. A no kinase control is also included. The measurements shown are the average values 
from duplicated experiments and the error bar indicates the high and low values. A maximum of <7% of 
total 
32
P is incorporated in the assays. 
 
Next, we applied 2-NM-PP1 on transfected CHO cells expressing either wildtype 
or analog-sensitive EGFR protein, and showed that this bumped inhibitor can selectively 
inhibit the kinase activity of analog-sensitive EGFR in CHO cells (Figure 3). Ligand-
induced autophosphorylation of analog-sensitive (T766G) EGFR was nearly abolished at 
the presence of 3 µM 2-NM-PP1. On the other hand, the activity of wildtype EGFR was 
not affected by 2-NM-PP1 until the concentration of the inhibitor was raised by 10 fold 
(30 µM). Therefore, 2-NM-PP1 can be used as a selective inhibitor for analog-sensitive 
EGFR at low micromolar concentration. 
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Figure 3: 2-NM-PP1 preferentially inhibits cellular signaling by EGFR with analog-sensitive mutation. 
CHO cells were grown in 12 well dishes, transiently transfected with pcDNA3.1-EGFR (full-length, 
wildtype or T766G) constructs and serum-starved overnight. 48 hours post transfection, 2NM-PP1 was 
added to each well with indicated final concentrations from a 10 mM stock solution (in DMSO) and cells 
were maintained in 37 ºC for one additional hour. Afterwards, cells were placed on ice and stimulated with 
100 ng/ml final concentration of EGF. Cells were then washed with PBS and lysed in RIPA buffer and 
subjected to western blotting. PhosphoEGFR was detected by pY20 anti-phosphotyrosine antibody; total 
EGFR were monitored by anti-EGFR Ab12 (labvision) and anti-Actin blots were used as loading controls. 
Experiments were performed in duplicates. 
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We then applied the 2NM-PP1 in our cellular assay for ErbB3 kinase, and 
investigated whether the bumped inhibitor can affect signaling by analog-sensitive ErbB3 
mutant. In BaF3 cells co-expressing ErbB2/ErbB3, adding 2NM-PP1 resulted in 
decreased level of ligand-induced ErbB autophosphorylation in both cell lines carrying 
wildtype or T768G-mutated ErbB3 (Figure 4A). The decrease of ErbB 
autophosphorylation in wildtype ErbB2/ErbB3 applied with 2NM-PP1 suggested the 
presence of off-target effect. Although, comparing to cells carrying wildtype ErbB3, the 
decrease of autophosphorylation seemed more prominent in cells carrying T768G-
mutated ErbB3, such effect is not statistically significant in our subsequent repeats. 
Therefore, we cannot conclude whether the cellular effect we observed is due to 
inhibition of ErbB3 kinase by 2-NM-PP1 or its off-target effect. Similarly, in CHO cells 
expressing wildtype or T768G-mutated ErbB3, no apparent effect is observed for ligand-
induced Akt activation when 2NM-PP1 is applied (Figure 4B). It is too early to draw any 
conclusion from these results, since (1) we do not know whether 2-NM-PP1 binds 
preferentially to analog-sensitive ErbB3 and (2) we used the same cellular assays as in 
Chapter 1.4, in which the kinase-compromised ErbB3 mutants showed little effect. 
However, this bumped inhibitor approach is still promising for a more comprehensive 
study of ErbB3 kinase signaling using a proteomic approach, such as SILAC, at the 
absence of specific ErbB3 inhibitors. 
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Figure 4: Application of 2-NM-PP1 on cellular signaling of analog-sensitive ErbB3 mutant. (A) BaF3 cells 
stably co-expressing ErbB2 wildtype and either ErbB3 wildtype or analog-sensitive (T768G) ErbB3 mutant 
were serum-starved for 4 hours, then further incubated with 8 µM 2-NM-PP1 or DMSO control for 2 hours. 
Cells were then resuspended in PBS and stimulated with Nrg1β on ice for 10 minutes. (B) CHO cells were 
transiently transfected with pcDNA plasmids containing either ErbB3 wildtype or analog-sensitive (T768G) 
ErbB3 mutant. 24 hours after transfection, CHO cells were serum-starved overnight, and then incubated 
with indicated amount of 2-NM-PP1 for 1 hour before stimulated with 5 ng/ml of Nrg1β for 20 minutes at 
37 ºC. Samples were prepared in the same way as described in Experimental Procedures. 
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2.2 Using Bumped ATPs as Preferred Substrates for Analog-sensitive ErbB Kinase 
Bumped ATPs have been used in multiple studies to identify the direct physiologic 
substrate of the engineered analog-sensitive kinase as well as study substrate specificity 
in cells (Elphick, Lee et al. 2007). Briefly, a 
32
P-label can be incorporated into the γ 
phosphate group of bumped ATP. Then the 
32
P label can be used to trace the substrates 
that are directly phosphorylated by this analog sensitive kinase in cells, since (at least in 
an ideal situation) only the engineered analog-sensitive kinase, but not the wildtype 
kinases, can utilize the 
32
P labeled bumped ATP as substrate. As a proof of principle, we 
first used this approach to study EGFR kinase (as it is ~1000 fold more active than ErbB3 
kinase). The goal is to investigate whether 
32
P labeled bumped ATP can be used to 
identify the physiological substrate of EGFR kinase in cells. This study can be broken 
down into four stages: 
1) Generation of bumped ATP 
2) Test whether analog-sensitive EGFR kinase can effectively utilize bumped ATP 
3) Development of membrane permeabilization method that allows bumped ATP to pass 
through plasma membrane and enter cytosol 
4) Using bumped ATP to trace protein phosphorylation mediated directly by EGFR 
1) Generation of γ-32P labeled bumped ATP ([γ-32P] N6-Bn-ATP) 
Due to the relative short half life (~14 days) of 
32P, γ-32P labeled bumped ATP needs to 
be generated shortly before the cellular assay. This is achieved by transferring γ-32P 
phosphate from fresh [γ-32P]ATP onto bumped-ADP using purified recombinant yeast 
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nucleoside diphosphate kinase (yNDPK) (Figure 5A). Briefly, the γ-32P phosphate is first 
transferred from ATP to a histidine side chain on yNDPK protein to form an unstable 
phosphate-protein intermediate and ADP. ADP can be washed away and bumped ADP is 
then added to take the γ-32P phosphate from yNDPK to form [γ-32P]bumped-ATP. Using 
this method, we have generated [γ-32P] N6-Benzyl-ATP ([γ-32P] N6-Bn-ATP), the most 
commonly used bumped ATP, with a protocol adapted from (Elphick et al. ACS 
Chemical Biology 2007). The radioactivity generated by each step is monitored by 
scintillation counter (Figure 5B). 
 Immobilize 0.1mg purified, recombinant yNDPK (6x His tagged) with 20ul NiNTA 
beads in 1ml resuspension buffer (RSB: 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% 
Glycerol), and wash once with RSB. 
 Incubate the beads with 50uCi 32P-ATP in 1ml RSB, and continue mixing on nutator 
for 5 min.  
 Spin down NiNTA beads at 500 g, remove the solution. (Figure 5B column 1 shows 
the remaining [γ-32P]ATP in solution after incubation with yNDPK.) 
 Wash three times with RSB + 1x phosphate (10 mM Na2HPO4, 2 mM KH2PO4). 
(Figure 5B column 2-4)  
 Wash once with RSB + 1x phosphate + 10 µM adenosine. (Figure 5B column 5) 
 Wash twice with RSB without phosphate. (Figure 5B column 6) 
 Incubate with 5nmol of N6-Bn-ADP in 200ul RSB + 10mM MgCl2 for 5 min. Spin 
down the beads and transfer the solution to another tube. The solution contains the 
newly generated [γ-32P] N6-Bn-ATP, which has incorporated ~60% of the initial 32P.  
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(Figure 5B column 7 shows the radioactivity of [γ-32P]N6-Bn-ATP, column 8 shows 
the remaining 
32
P left on NiNTA beads) 
 Make aliquots and freeze in -20 ˚C. 
 
Figure 5 Generation of radioactive bumped ATP. (A) Diagram showing the transfer of [γ-32P] from ATP to 
bumped ATP using yNDPK (adapted from (Elphick, Lee et al. 2007)). (B) Tracking the radioactive signal 
generated in each step during a typical preparation. 1% of the solution from each step is used to monitor its 
radioactivity using scintillation counter. Numbers are averaged from duplicated measurements. 
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2) Test whether analog-sensitive EGFR kinase can effectively utilize bumped ATP  
EGFR kinase is used as a model to investigate whether the chemical genetic approach 
with bumped ATP can be applied to ErbB kinases. In an in vitro radioactive kinase assay, 
both wildtype and T766G-mutated EGFR kinase can effectively utilize [γ-32P]ATP as 
substrate, whereas only analog-sensitive (T766G) EGFR kinase can utilize  [γ-32P]N6-
Bn-ATP (Figure 6). Based on the readings from scintillation counter, we conclude that 
T766G-mutated EGFR kinase utilizes [γ-32P]N6-Bn-ATP >100 times more efficiently 
than wildtype EGFR kinase.  
 
 
Figure 6: Bumped ATP (N6-Bn-ATP) can only be utilized by analog sensitive EGFR kinase but not 
wildtype EGFR kinase. In the kinase assays, 1 µM purified recombinant EGFR kinase domain (wildtype or 
T766G) is incubated with 100 µM ATP, ~1 µCi [γ-32P]ATP (or [γ-32P]N6-Bn-ATP), 200 µM poly GluTyr 
peptide substrate and 5 mM MgCl2 for 5 minutes at room temperature. The reactions are stopped with 
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100mM EDTA and spotted onto nitrocellulose paper for washing and scintillation counting to measure the 
incorporation of 
32
P. A no kinase control is also included. The measurements shown are the average values 
from duplicated experiments and the error bars represent one standard deviation. A maximal of 20% of 
total 
32
P is incorporated in the assays. 
3) Development of membrane permeabilization method that allows bumped ATP to pass 
through plasma membrane and enter into cytosol. 
Permeabilization of cell membrane is needed for the negatively charged [γ-32P]N6-Bn-
ATP to enter into cytosol and be utilized by kinases. At the same time, the disruption of 
cell membrane shall not interfere with ligand-induced ErbB dimerization/activation. We 
have shown that digitonin-permeabilization can meet such requirements, as demonstrated 
in both ErbB3 activation in T47D cells (Figure 7A) and EGFR activation in CHO cells 
(Figure 7B). In these experiments, cell pellets were mixed with equal volume of PBS (for 
intact cells) or cell lysis buffer (CLB, for permeabilizaed cells) containing 10 mM Tris 
pH 7.4, 150mM NaCl, protease inhibitors (1 mM PMSF, 10 µM leupeptin and 10 µM 
aprotinin), phosphatase inhibitors (25 mM NaF, 5 mM Na2MoO4 and 0.2 mM Na3VO4) 
and varying amount of digitonin (CALBIOCHEM  Cat# 300410). Cell permeabilization 
was then verified by trypan blue staining and followed with ligand stimulation 
experiments. Reactions were stopped with 100 mM EDTA pH 8.0, and samples were 
prepared for SDS-PAGE and Western blotting. 
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Figure 7 Permeabilization of cell membrane with digitonin does not affect ligand induced ErbB signaling. 
(A) Parental T47D cells were serum-starved overnight, detached from flasks with PBS+EDTA, washed in 
PBS, and then resuspended in cold PBS (for intact cells) or CLB buffer containing 0.05% (m/v) digitonin 
(for permeabilized cells). The volume of the resuspension buffer is equal to the volume of the cell pellet. 
Then 5mM MgCl2 and optional 1 mM ATP were added to permeabilized cells. Cells were then stimulated 
with Nrg1β (40 ng/ml) for 5 minutes on ice and processed for Western blotting. (B) CHO cells transiently 
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transfected with EGFR (wildtype or T766G) were serum-starved overnight, washed and resuspended in 
cold PBS (for intact cells) or CLB buffer containing 0.01% (m/v) digitonin, 5mM MgCl2 and 0.5 mM ATP. 
Cells were then stimulated with EGF (100 ng/ml) for 5 minutes on ice (for intact cells) or 3 minutes at 
room temperature (for permeabilized cells) and processed for Western blotting. 
 
4) Using bumped ATP to trace protein phosphorylation mediated directly by EGFR 
We have applied [γ-32P]N6-Bn-ATP to permeabilized cells expressing wildtype or 
analog-sensitive (T766G) EGFR mutant and, after ligand stimulation experiement, used a 
radioactive phospho-image gel to look for protein substrates that carried the 
32
P 
phosphate. Unfortunately, we could not identify any unique (or prefered) protein 
substrates in cells expressing T766G-mutated EGFR yet, due to the high background 
32
P 
signals (many non-specifically labeled bands on the SDS-PAGE gel) in the assay. The 
main reasons for the high background signal are (a) many endogenous wildtype kinases 
can still utilize the bumped ATP as substrate at appreciable rates and (b) the γ-32P 
phosphate on [γ-32P]N6-Bn-ATP can be rapidly transferred onto other nucleotide 
diphosphate (NDPs) by endogenous NDPK in cells, which can then be effectively 
utilized by wildtype kinases. 
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